Alere 10-Q 17 Aug 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Aug. 12, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	ALR
Entity Registrant Name	ALERE INC.
Entity Central Index Key	1,145,460
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		86,740,318

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Net product sales	$ 459,771	$ 484,338
Services revenue	115,709	123,856
Net product sales and services revenue	575,480	608,194
License and royalty revenue	2,729	4,698
Net revenue	578,209	612,892
Cost of net product sales	237,461	240,101
Cost of services revenue	73,100	75,626
Cost of net product sales and services revenue	310,561	315,727
Cost of license and royalty revenue	1,391	1,950
Cost of net revenue	311,952	317,677
Gross profit	266,257	295,215
Operating expenses:
Research and development	27,062	28,016
Sales and marketing	99,813	109,079
General and administrative	114,956	92,691
Impairment and (gain) loss on dispositions, net	(3,810)	34,792
Operating income (loss)	28,236	30,637
Interest expense, including amortization of original issue discounts and deferred financing costs	(42,106)	(46,431)
Other income (expense), net	(1,349)	(2,367)
Loss from continuing operations before benefit for income taxes	(15,219)	(18,161)
Benefit for income taxes	(208)	(7,853)
Loss from continuing operations before equity earnings of unconsolidated entities, net of tax	(15,011)	(10,308)
Equity earnings of unconsolidated entities, net of tax	5,034	3,959
Income (loss) from continuing operations	(9,977)	(6,349)
Income from discontinued operations, net of tax	0	216,777
Net income (loss)	(9,977)	210,428
Less: Net income attributable to non-controlling interests	103	88
Net income (loss) attributable to Alere Inc. and Subsidiaries	(10,080)	210,340
Preferred stock dividends	(5,309)	(5,250)
Net income (loss) available to common stockholders	$ (15,389)	$ 205,090
Basic and diluted net income (loss) per common share:
Loss from continuing operations	$ (0.18)	$ (0.14)
Income from discontinued operations	0	2.57
Net income (loss) per common share	$ (0.18)	$ 2.43
Weighted-average shares - basic and diluted	86,646	84,338

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (9,977)	$ 210,428
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	22,193	(80,342)
Minimum pension liability adjustment	155	(1,382)
Other comprehensive income (loss), before tax	22,348	(81,724)
Other comprehensive income (loss)	22,348	(81,724)
Comprehensive income	12,371	128,704
Less: Comprehensive income attributable to non-controlling interests	103	88
Comprehensive income attributable to Alere Inc. and Subsidiaries	$ 12,268	$ 128,616

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 490,663	$ 502,200
Restricted cash	6,166	5,694
Marketable securities	71	164
Accounts receivable, net of allowances of $87,710 and $89,701 at March 31, 2016 and December 31, 2015, respectively	459,292	445,833
Inventories, net	350,931	347,001
Prepaid expenses and other current assets	144,369	152,233
Assets held for sale current	0	4,165
Total current assets	1,451,492	1,457,290
Property, plant and equipment, net	445,218	446,039
Goodwill	2,839,692	2,836,915
Other intangible assets with indefinite lives	28,760	28,110
Finite-lived intangible assets, net	962,633	997,281
Restricted cash	43,388	43,228
Other non-current assets	17,927	18,078
Investments in unconsolidated entities	74,744	65,333
Deferred tax assets	16,124	13,993
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	11,813	13,337
Total assets	5,895,308	5,923,121
Current liabilities:
Short-term debt and current portion of long-term debt	193,044	199,992
Current portion of capital lease obligations	4,048	3,962
Accounts payable	165,800	195,752
Accrued expenses and other current liabilities	315,995	324,465
Liabilities related to assets held for sale - current	0	363
Total current liabilities	678,887	724,534
Long-term liabilities:
Long-term debt, net of current portion	2,823,654	2,831,166
Capital lease obligations, net of current portion	7,654	7,181
Deferred tax liabilities	144,483	147,618
Other long-term liabilities	155,842	154,193
Total long-term liabilities	3,131,633	3,140,158
Commitments and contingencies
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at March 31, 2016 and December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at March 31, 2016 and December 31, 2015; Outstanding: 1,774 shares at March 31, 2016 and December 31, 2015	606,468	606,468
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,415 shares at March 31, 2016 and 94,043 shares at December 31, 2015, respectively; Outstanding: 86,736 shares at March 31, 2016 and 86,364 shares at December 31, 2015, respectively	94	94
Additional paid-in capital	3,452,722	3,438,732
Accumulated deficit	(1,476,461)	(1,466,381)
Treasury stock, at cost, 7,679 shares at March 31, 2016 and December 31, 2015	(184,971)	(184,971)
Accumulated other comprehensive loss	(317,429)	(339,777)
Total stockholders' equity	2,080,423	2,054,165
Non-controlling interests	4,365	4,264
Total equity	2,084,788	2,058,429
Total liabilities and equity	$ 5,895,308	$ 5,923,121

Consolidated Balance Sheets (u5

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 87,710	$ 89,701
Series B preferred stock, par value	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,763	$ 709,763
Series B preferred stock, shares authorized	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	94,415,000	94,043,000
Common stock, shares outstanding	86,736,000	86,364,000
Treasury stock, shares	7,679,000	7,679,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows from Operating Activities:
Net income (loss)	$ (9,977)	$ 210,428
Income from discontinued operations, net of tax	0	216,777
Loss from continuing operations	(9,977)	(6,349)
Adjustments to reconcile loss from continuing operations to net cash (used in) provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	2,236	3,946
Depreciation and amortization	72,504	74,414
Non-cash stock-based compensation expense	9,602	5,149
Impairment of inventory	1,349	78
Impairment of long-lived assets	608	(69)
Loss on disposition of fixed assets	323	1,391
Equity earnings of unconsolidated entities, net of tax	(5,034)	(3,959)
Deferred income taxes	(6,812)	(21,418)
(Gain) loss on dispositions	(3,810)	34,792
Other non-cash items	2,496	8,181
Non-cash change in fair value of contingent purchase price consideration	142	(14,035)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(9,199)	(11,755)
Inventories, net	(14,147)	(29,705)
Prepaid expenses and other current assets	(5,796)	18,980
Accounts payable	(31,542)	(18,648)
Accrued expenses and other current liabilities	(7,413)	(1,282)
Other non-current liabilities	14	(7,348)
Cash paid for contingent consideration	(143)	(3,654)
Net cash (used in) provided by continuing operations	(4,599)	28,709
Net cash provided by discontinued operations	0	318
Net cash (used in) provided by operating activities	(4,599)	29,027
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	(436)	71
Purchases of property, plant and equipment	(14,504)	(25,647)
Proceeds from sale of property, plant and equipment	612	808
Cash received from business disposition, net of cash divested	21,470	581,185
Cash paid for business acquisitions, net of cash acquired	(5,945)	0
Cash received from sales of marketable securities	93	86
Cash received from equity method investments	2,205	0
Cash paid for investments	(184)	0
(Increase) decrease in other assets	(540)	913
Net cash provided by (used in) continuing operations	2,771	557,416
Net cash used in discontinued operations	0	(209)
Net cash provided by (used in) investing activities	2,771	557,207
Cash Flows from Financing Activities:
Cash paid for financing costs	(1)	(59)
Cash paid for contingent purchase price consideration	(145)	(4,696)
Proceeds from issuance of common stock, net of issuance costs	11,124	34,632
Proceeds from issuance of long-term debt	325	15
Payments on short-term debt	0	(321)
Payments on long-term debt	(17,275)	(463,011)
Net payments under revolving credit facilities	(127)	(127,050)
Cash paid for dividends	(5,323)	(5,323)
Principal payments on capital lease obligations	(1,107)	(1,484)
Net cash used in continuing operations	(12,529)	(567,297)
Net cash used in discontinued operations	0	(76)
Net cash used in financing activities	(12,529)	(567,373)
Foreign exchange effect on cash and cash equivalents	2,820	(6,127)
Net (decrease) increase in cash and cash equivalents	(11,537)	12,734
Cash and cash equivalents, beginning of period - continuing operations	502,200	378,461
Cash and cash equivalents, beginning of period - discontinued operations	0	23,300
Cash and cash equivalents, end of period	490,663	414,495
Less: Cash and cash equivalents of discontinued operations, end of period	0	0
Cash and cash equivalents of continuing operations, end of period	$ 490,663	$ 414,495

Basis of Presentation of Financ

Basis of Presentation of Financial Information	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	(1) Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2015 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on August 8, 2016. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015. Certain amounts presented may not recalculate directly, due to rounding.

Revision of Previously Reported

Revision of Previously Reported Consolidated Financial Statements	3 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Revision of Previously Reported Consolidated Financial Statements	(2) Revision of Previously Reported Consolidated Financial Statements In connection with the preparation of our consolidated financial statements for the fiscal year ended December 31, 2015, we determined that, in fiscal years 2013 and 2014, each of the interim periods of 2014 and the first three quarters of fiscal year 2015, we had incorrectly reported the timing of recognition of certain revenue transactions for such periods. As a result, we revised our consolidated financial statements as of December 31, 2014 and for the fiscal years ended December 31, 2014 and 2013, each of the interim periods of 2014 and the first three quarters of fiscal year 2015. Specifically, the errors in the application of U.S. GAAP rules regarding the timing of revenue recognition primarily relate to: (i) transactions, principally in Africa, in which we recognized revenue when the product shipped to the distributor, but we contractually retained title in the products until the distributor paid for the products in full or the distributor was not obligated to pay us until the products were sold through to the end-user; (ii) “bill and hold” transactions, principally in China, which did not meet the criteria for revenue recognition under U.S. GAAP; and (iii) other transactions, in which we recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer. These errors required adjustments to the period in which certain revenues were recognized so that such revenues are recognized in the period in which: physical delivery occurred as defined by the contractual relationship; title and risk of loss had transferred to the buyer; or the buyer had the contractual obligation to pay the amounts invoiced, as required by U.S. GAAP revenue recognition rules and our accounting policy relating to revenue recognition. The adjustments recorded in connection with the revisions to the three months ended March 31, 2015 relate to a $4.7 million increase in revenue due to the aforementioned revenue recognition issues. Additionally, we have reflected other out-of-period adjustments in the periods in which such adjustments originated. These adjustments were identified during the financial closing process in connection with the fiscal years ended December 31, 2014 and 2013 and the first three quarters of fiscal year 2015. The financial statements included in this Quarterly Report on Form 10-Q have been adjusted to include the adjustments in the period in which these items originated. Because these out-of-period adjustments are treated as corrections to our prior period financial results, the financial information included in this Quarterly Report on Form 10-Q has been revised. Specifically, these adjustments include a $1.5 million increase in cost of net product sales, a $1.1 million increase in other expenses due to errors in the measurement of a royalty obligation and the income tax impact of these adjustments. Although management has determined that the errors, as well as the revenue recognition issues noted in the preceding paragraphs, individually and in the aggregate, are not material to prior periods, the financial statements for the three months ended March 31, 2015 included herein have been revised to correct for the impact of these items. Unless otherwise indicated, the consolidated financial information as of and for the three months ended March 31, 2015 presented in this Quarterly Report on Form 10-Q reflects these revisions. The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts: Three Months Ended March 31, 2015 Revised Consolidated Statement of Operations (in thousands) As Previously Revision As Net product sales $ 479,599 $ 4,739 $ 484,338 Net product sales and services revenue $ 603,455 $ 4,739 $ 608,194 Net revenue $ 608,153 $ 4,739 $ 612,892 Cost of net product sales $ 238,637 $ 1,464 $ 240,101 Cost of services revenue $ 75,581 $ 45 $ 75,626 Cost of net product sales and services revenue $ 314,218 $ 1,509 $ 315,727 Cost of net revenue $ 316,168 $ 1,509 $ 317,677 Gross profit $ 291,985 $ 3,230 $ 295,215 Operating income $ 27,407 $ 3,230 $ 30,637 Other income (expense), net $ (1,270 ) $ (1,097 ) $ (2,367 ) Loss from continuing operations before benefit for income taxes $ (20,294 ) $ 2,133 $ (18,161 ) Benefit (provision) for income taxes $ (8,786 ) $ 933 $ (7,853 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax $ (11,508 ) $ 1,200 $ (10,308 ) Income (loss) from continuing operations $ (7,549 ) $ 1,200 $ (6,349 ) Net income $ 209,228 $ 1,200 $ 210,428 Net income attributable to Alere Inc. and Subsidiaries $ 209,140 $ 1,200 $ 210,340 Net income available to common stockholders $ 203,890 $ 1,200 $ 205,090 Basic and diluted net income (loss) per common share: Net income (loss) from continuing operations $ (0.15 ) $ 0.01 $ (0.14 ) Basic and diluted net income per common share: Net income per common share $ 2.42 $ 0.01 $ 2.43 Three Months Ended March 31, 2015 Revised Consolidated Statement of Comprehensive Income (in thousands) As Previously Revision As Revised Net income $ 209,228 $ 1,200 $ 210,428 Comprehensive income $ 127,504 $ 1,200 $ 128,704 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 127,416 $ 1,200 $ 128,616 Three Months Ended March 31, 2015 Revised Consolidated Statement of Cash Flows (In thousands) As Previously Revision As Net income $ 209,228 $ 1,200 $ 210,428 Loss from continuing operations $ (7,549 ) $ 1,200 $ (6,349 ) Depreciation and amortization $ 74,368 $ 46 $ 74,414 Deferred income taxes $ (20,349 ) $ (1,069 ) $ (21,418 ) Accounts receivable, net $ (16,881 ) $ 5,126 $ (11,755 ) Inventories, net $ (31,168 ) $ 1,463 $ (29,705 ) Accrued expenses and other current liabilities $ 5,484 $ (6,766 ) $ (1,282 ) Other non-current liabilities $ (7,997 ) $ 649 $ (7,348 ) Net cash provided by operating activities $ 28,378 $ 649 $ 29,027 Excess tax benefits on exercised stock options $ 649 $ (649 ) $ — Net cash used in financing activities $ (566,724 ) $ (649 ) $ (567,373 ) We have also reflected these corrections as applicable in our consolidated financial statements and our consolidating financial statements presented in Note 22 Guarantor Financial Information

Merger Agreement

Merger Agreement	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Merger Agreement	(3) Merger Agreement Merger Agreement with Abbott Laboratories On January 30, 2016, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Abbott Laboratories, or Abbott. The Merger Agreement provides for the merger of a newly formed, wholly owned subsidiary of Abbott with and into Alere, or the merger, with Alere surviving the merger as a wholly owned subsidiary of Abbott, or the surviving corporation. Under the terms of the Merger Agreement, holders of shares of our common stock will receive $56.00 in cash, without interest, in exchange for each share of common stock. Each share of our Series B Convertible Perpetual Preferred Stock, par value $0.001 per share, or Series B Preferred Stock, issued and outstanding immediately prior to the effective time of the merger will remain issued and outstanding immediately following the consummation of the merger as one share of Series B Convertible Preferred Stock, par value $0.001 per share, of the surviving corporation. The Merger Agreement was approved by our board of directors. Completion of the merger is subject to customary closing conditions, including (1) the adoption of the Merger Agreement by the affirmative vote of the holders of at least a majority of all outstanding shares of our common stock, (2) there being no judgment or law enjoining or otherwise prohibiting the consummation of the merger and (3) the expiration of the waiting period applicable to the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, and receipt of other required antitrust approvals. The obligation of each of the parties to consummate the merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Merger Agreement. The Merger Agreement contains certain termination rights and provides that, upon termination of the Merger Agreement under certain circumstances, Alere would be required to pay Abbott a termination fee equal to $177.0 million. We currently expect that the transaction will close by the end of 2016. On May 2, 2016, Abbott and Alere received a request for additional information, or a “second request,” from the United States Federal Trade Commission, or the FTC, relating to Abbott’s potential acquisition of Alere. The second request was issued under the HSR Act. In addition, Abbott has agreed voluntarily to provide the FTC at least 60 days advance notice before certifying substantial compliance with the second request and to extend the waiting period imposed by the HSR Act until 60 days after Abbott and Alere have substantially complied with the second request, unless the period is further extended voluntarily by the parties or terminated sooner by the FTC. On June 23, 2016, Abbott and Alere received a request for additional information, or a “supplemental information request,” from the Canadian Competition Bureau, or the Bureau, relating to Abbott’s potential acquisition of Alere. The supplemental information request was issued under the Competition Act of Canada, or the Competition Act. The effect of the supplemental information request is to extend the waiting period imposed by the Competition Act until 30 days after Abbott and Alere have each complied with the supplemental information request, unless the period is extended voluntarily by the parties or terminated sooner by the Bureau. Under the terms of the Merger Agreement, Abbott has agreed to make certain divestitures if necessary to obtain the consent of the antitrust authorities to the transaction contemplated by the Merger Agreement, subject to certain materiality exceptions provided for in the Merger Agreement.

Discontinued Operations, Impair

Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	3 Months Ended
	Mar. 31, 2016
Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	(20) Impairment and (Gain) Loss on Dispositions, Net In January 2016, we completed the sale of our Alere E-Santé business, which was a component of our professional diagnostics reporting unit and business segment. We received cash consideration of approximately $8.1 million, net of a final working capital adjustment totaling approximately $0.2 million, and we are eligible to receive up to $1.5 million of contingent cash consideration. As a result of this transaction, we recorded a $3.8 million gain in the three months ended March 31, 2016 on the disposition of the Alere E-Santé business. In March 2015, we sold certain assets of our AdnaGen GmbH business, which was part of our professional diagnostics reporting unit and business segment, for approximately $4.6 million in cash proceeds and, as a result of this transaction, we recorded a loss of $0.3 million during the three months ended March 31, 2015. In March 2015, we sold our Gesellschaft fur Patientenhilfe DGP GmbH subsidiary, which was part of our professional diagnostics reporting unit and business segment, for €7.6 million (approximately $8.2 million at March 31, 2015) and, as a result of this transaction, we recorded a loss on disposition of $7.5 million during the three months ended March 31, 2015. The financial results for the above businesses are immaterial to our consolidated financial results.
Health Management Business [Member]
Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	(4) Discontinued Operations On January 9, 2015, we completed the sale of our health management business to OptumHealth Care Solutions for a purchase price of $599.9 million. We used the net cash proceeds of the sale to repay $575.0 million in aggregate principal amount of outstanding indebtedness under our prior credit facility. The following summarized financial information related to the health management business has been segregated from continuing operations and reported as discontinued operations in our consolidated statement of operations for the three months ended March 31, 2015. The results are as follows (in thousands): Three Months Ended Net revenue $ 7,373 Cost of net revenue (4,413 ) Sales and marketing (996 ) General and administrative (5,001 ) Interest expense (9 ) Other income (expense), net 160 Gain on disposal 366,191 Income from discontinued operations before provision for income taxes 363,305 Provision for income taxes 146,528 Income from discontinued operations, net of tax $ 216,777

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2016
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(5) Cash and Cash Equivalents We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2016, our cash equivalents consisted of money market funds.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventories	(6) Inventories Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): March 31, 2016 December 31, 2015 Raw materials $ 125,111 $ 130,171 Work-in-process 75,625 69,178 Finished goods 150,195 147,652 $ 350,931 $ 347,001

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	(7) Stock-based Compensation We recorded stock-based compensation expense in our consolidated statements of operations for the three months ended March 31, 2016 and 2015 as follows (in thousands): Three Months Ended March 31, 2016 2015 Cost of net revenue $ 479 $ 253 Research and development 398 324 Sales and marketing 1,925 1,094 General and administrative 6,800 3,478 9,602 5,149 Benefit for income taxes — (2,373 ) Stock-based compensation, net of tax $ 9,602 $ 2,776

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Income (Loss) per Common Share	(8) Net Income (Loss) per Common Share The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2016 and 2015 (in thousands, except per share amounts): Three Months Ended March 31, 2016 2015 Basic and diluted net income (loss) per common share: Numerator: Loss from continuing operations $ (9,977 ) $ (6,349 ) Preferred stock dividends (5,309 ) (5,250 ) Loss from continuing operations attributable to common shares (15,286 ) (11,599 ) Less: Net income attributable to non-controlling 103 88 Loss from continuing operations attributable to Alere Inc. and Subsidiaries (15,389 ) (11,687 ) Income from discontinued operations — 216,777 Net income (loss) available to common stockholders $ (15,389 ) $ 205,090 Denominator: Weighted-average common shares outstanding – basic and diluted 86,646 84,338 Basic and diluted net income (loss) per common share: Loss from continuing operations attributable to Alere Inc. and Subsidiaries $ (0.18 ) $ (0.14 ) Income from discontinued operations — 2.57 Basic and diluted net income (loss) per common share $ (0.18 ) $ 2.43 The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands): Three Months Ended March 31, 2016 2015 Denominator: Options to purchase shares of common stock 7,378 7,882 Warrants — 4 Conversion shares related to 3% convertible senior subordinated notes 3,411 3,411 Conversion shares related to subordinated convertible promissory notes — 27 Conversion shares related to Series B convertible preferred stock 10,239 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 21,028 21,563

Stockholders' Equity and Non-co

Stockholders' Equity and Non-controlling Interests	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity and Non-controlling Interests	(9) Stockholders’ Equity and Non-controlling Interests (a) Preferred Stock For both the three months ended March 31, 2016 and 2015, Series B preferred stock dividends amounted to $5.3 million, which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the periods. As of March 31, 2016, $5.3 million of Series B preferred stock dividends was accrued. As of April 15, 2016, payments have been made covering all dividend periods through March 31, 2016. The Series B preferred stock dividends for the three months ended March 31, 2016 and 2015 were paid in cash in the subsequent quarters. (b) Changes in Stockholders’ Equity and Non-controlling Interests A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2016 is provided below (in thousands): Three Months Ended March 31, 2016 Total Stockholders’ Equity Non- Interests Total Equity Equity, beginning of period $ 2,054,165 $ 4,264 $ 2,058,429 Issuance of common stock under employee compensation plans 11,123 — 11,123 Net issuance of common stock to settle taxes on restricted stock units (1,412 ) — (1,412 ) Preferred stock dividends (5,323 ) — (5,323 ) Stock-based compensation expense 9,602 — 9,602 Excess tax benefits on exercised stock options — — — Other adjustments — (2 ) (2 ) Net income (loss) (10,080 ) 103 (9,977 ) Total other comprehensive income (loss) 22,348 — 22,348 Equity, end of period $ 2,080,423 $ 4,365 $ 2,084,788

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Business Combinations	(10) Business Combinations Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Net assets acquired are recorded at their estimated fair value and are subject to adjustment upon finalization of the fair value analysis. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. (a) Acquisition in 2016 EDTS On February 11, 2016, we acquired the shares of European Drug Testing Services EDTS AB, or EDTS, located in Lidingo, Sweden, a provider of services related to on-site drug testing. The aggregate purchase price was approximately $6.5 million and was paid in cash. The operating results of EDTS are included in our professional diagnostics reporting unit and business segment. Our consolidated statements of operations for the three months ended March, 31, 2016 included revenue totaling approximately $0.9 million related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $2.1 million, which is deductible for tax purposes. A summary of the preliminary fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,053 Intangible assets 4,220 Total assets acquired $ 7,759 Current liabilities $ 1,301 Total liabilities assumed $ 1,301 Net assets acquired $ 6,458 Cash paid $ 6,458 The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective preliminary fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- average Useful Life Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete agreements 570 3.0 years Total intangible assets $ 4,220

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring	(11) Restructuring The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three months ended March 31, 2016 and 2015 (in thousands): Three Months Ended March 31, Statement of Operations Caption 2016 2015 Cost of net revenue 1,267 1,502 Research and development 1,920 493 Sales and marketing 650 1,383 General and administrative 3,826 892 Total operating expenses 7,663 4,270 Interest expense, including amortization of original issue discounts and deferred financing costs 5 7 Total charges 7,668 4,277 (a) Restructuring Plans During 2016, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our manufacturing and supply chain, and research and development groups, as well as closing certain business locations in Europe and the United States. The following table summarizes the restructuring activities related to our 2016 restructuring plans, in addition to our earlier restructuring plans as disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, for the three months ended March 31, 2016 and 2015 and since inception of these restructuring plans (in thousands): Three Months Ended March 31, Since 2016 2015 Inception Professional Diagnostics Severance-related costs $ 3,091 $ 2,800 $ 41,078 Facility and transition costs 981 1,426 12,649 Other exit costs 5 7 827 Cash charges 4,077 4,233 54,554 Fixed asset and inventory impairments 398 9 16,351 Other non-cash charges 213 — 2,195 Total professional diagnostics charges $ 4,688 $ 4,242 $ 73,100 Corporate and Other Severance-related costs $ 15 $ 42 $ 4,292 Facility and transition costs 2,965 (7 ) 14,287 Total corporate and other charges $ 2,980 $ 35 $ 18,579 Total restructuring charges $ 7,668 $ 4,277 $ 91,679 We anticipate incurring approximately $3.2 million and $5.9 million in additional costs under our 2016 restructuring plans related to our professional diagnostics and corporate and other business segments, respectively, primarily related to integration and operational initiatives and site closures. We may develop additional restructuring plans over the remainder of 2016. In addition, we anticipate incurring approximately $3.8 million in additional costs under earlier restructuring plans related to our professional diagnostics segment and corporate and other segment as in effect at March 31, 2016, primarily related to the closure of our manufacturing facility in Israel. (b) Restructuring Reserves The following table summarizes our restructuring reserves related to the plans described above, of which $6.1 million is included in accrued expenses and other current liabilities and $1.0 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 3,106 3,946 5 7,057 Payments (1,904 ) (1,897 ) (36 ) (3,837 ) Currency adjustments 45 37 — 82 Balance, March 31, 2016 $ 2,880 $ 4,052 $ 149 $ 7,081

Long-term Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Long-term Debt	(12) Long-term Debt We had the following long-term debt balances outstanding (in thousands): March 31, 2016 December 31, 2015 A term loans (1)(2) $ 568,955 $ 575,746 B term loans (1)(2) 963,656 965,740 7.25% Senior notes (2) 446,689 446,320 6.5% Senior subordinated notes (2) 419,533 419,209 6.375% Senior subordinated notes (2) 418,362 418,133 3% Convertible senior subordinated notes (3) 149,960 149,839 Other lines of credit 22 136 Other 49,521 56,035 3,016,698 3,031,158 Less: Short-term debt and current portion of long-term debt (193,044 ) (199,992 ) Long-term debt $ 2,823,654 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 12, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, this Quarterly Report on Form 10-Q and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing such notes. (3) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015 and March 31, 2016, as these notes matured (and were fully paid and discharged) in May 2016. In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three months ended March 31, 2016 and 2015 as follows (in thousands): Three Months Ended March 31, 2016 2015 Secured credit facility (1) $ 17,043 $ — Prior credit facility (2) — 19,462 7.25% Senior notes 8,524 8,524 6.375% Senior subordinated notes 7,003 — 6.5% Senior subordinated notes 7,231 7,233 8.625% Senior subordinated notes — 9,273 3% Convertible senior subordinated notes 1,244 1,246 Other 1,060 693 $ 42,105 $ 46,431 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. For the three months ended March 31, 2016 and 2015, the amounts include $0.0 million and $0.4 million, respectively, related to the amortization of fees paid for certain debt modifications. April 2016 Amendment to Secured Credit Facility and May 2016 Waivers with respect to Senior Notes and Senior Subordinated Notes On April 22, 2016, we and the requisite lenders under the Credit Agreement entered into an amendment to the Credit Agreement pursuant to which they agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and certain related deliverables for the year ended December 31, 2015 by the applicable deadline under the Credit Agreement, (y) any restatement of certain financial statements as a result of our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, or (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach is discovered as part of the audit of our financial statements for the year ended December 31, 2015, to the extent that such breach is due to our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, and (ii) extend the deadlines for delivery of the financial statements for the year ended December 31, 2015, the financial statements for the quarter ended March 31, 2016 and certain related deliverables. Under the terms of this amendment, we are required to deliver our unaudited financial statements for the three months ended March 31, 2016 and certain related deliverables on or before August 18, 2016, and our failure to do so could give rise to an Event of Default under the Credit Agreement and may result in the acceleration of the amounts due thereunder. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.250% of the sum of (i) the aggregate principal amount of such lender’s Term Loans outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment (each as defined in the Credit Agreement) outstanding on the effective date of the amendment, or approximately $4.5 million in the aggregate for all consenting lenders. The amendment also increases the applicable interest rate margins for all loans outstanding under our secured credit facility by 0.25% per annum for the period from July 1, 2016 to the date of delivery of such financial reports and related deliverables under our secured credit facility. See Note 23 Subsequent Events In addition, on April 29, 2016, we commenced consent solicitations relating to our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 7.25% senior notes, which we refer to collectively as the Notes. The consent solicitations were made to holders of record of the Notes as of April 28, 2016, and such solicitations were completed on May 9, 2016. Pursuant to the consent solicitations, the requisite holders of each series of Notes agreed to extend the deadline for delivery of certain financial information and to waive, through and until 5:00 p.m., New York City time, on August 31, 2016, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. and our subsequent Quarterly Reports on Form 10-Q, or the Failures to File. In connection with the Failures to File, we paid, in May and July 2016, to each holder of Notes who validly delivered a consent aggregate cash payments equal to $15.00 for each $1,000 aggregate principal amount of such holder’s Notes, or an aggregate of $19.2 million. Maturity of our 3.0% convertible senior subordinated notes Our 3% convertible senior subordinated notes matured on May 15, 2016. Based on the price of our common stock on the date of maturity, we paid all outstanding principal and accrued interest owing under such notes in cash. The aggregate amount paid to the noteholders at maturity was approximately $152.0 million, consisting of $125.0 million in cash drawn under our revolving credit facility plus $27.0 million of cash available on such date.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(13) Fair Value Measurements We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1— Level 2— Level 3— The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description March 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 71 $ 71 $ — $ — Total assets $ 71 $ 71 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,547 $ — $ — $ 57,547 Total liabilities $ 57,547 $ — $ — $ 57,547 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17(a) Commitments and Contingences Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2016 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (344 ) Fair value adjustments 143 Foreign currency adjustments 4 Fair value of contingent consideration obligations, March 31, 2016 $ 57,547 At March 31, 2016 and December 31, 2015, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. The carrying amount and estimated fair value of our long-term debt were $3.0 billion and $3.1 billion, respectively, at March 31, 2016. The carrying amount and estimated fair value of our long-term debt were $3.1 billion and $3.0 billion, respectively, at December 31, 2015. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

Financial Information by Segmen

Financial Information by Segment	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Financial Information by Segment	(14) Financial Information by Segment Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our current reportable operating segments are professional diagnostics, consumer diagnostics, and corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three months ended March 31, 2016 and 2015 is as follows (in thousands): Professional Consumer Corporate Total Three Months Ended March 31, 2016: Net revenue $ 560,768 $ 17,442 $ — $ 578,209 Operating income (loss) $ 82,679 $ 167 $ (54,610 ) $ 28,236 Gain on dispositions, net $ 3,810 $ — $ — $ 3,810 Depreciation and amortization $ 68,832 $ 1,499 $ 2,173 $ 72,504 Restructuring charges $ 4,688 $ — $ 2,980 $ 7,668 Stock-based compensation $ — $ — $ 9,602 $ 9,602 Three Months Ended March 31, 2015: Net revenue $ 590,924 $ 21,968 $ — $ 612,892 Operating income (loss) $ 89,543 $ 2,204 $ (61,110 ) $ 30,637 Impairment and (gain) loss on dispositions, net $ (1,731 ) $ — $ 36,523 $ 34,792 Depreciation and amortization $ 72,469 $ 711 $ 1,234 $ 74,414 Restructuring charges $ 4,235 $ — $ 35 $ 4,270 Stock-based compensation $ — $ — $ 5,149 $ 5,149 Assets: As of March 31, 2016 $ 5,627,777 $ 178,699 $ 88,832 $ 5,895,308 As of December 31, 2015 $ 5,619,901 $ 172,551 $ 130,669 $ 5,923,121 The following table summarizes our net revenue from the professional diagnostics reporting segment by groups of similar products and services for the three months ended March 31, 2016 and 2015 (in thousands): Three Months Ended March 31, 2016 2015 Cardiometabolic $ 194,577 $ 200,936 Infectious disease 183,234 185,402 Toxicology 146,783 148,756 Other 33,444 51,132 Total professional diagnostics net product sales and services revenue 558,038 586,226 License and royalty revenue 2,730 4,698 Total professional diagnostics net revenue $ 560,768 $ 590,924

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	(15) Related Party Transactions (a) SPD Joint Venture In May 2007, we completed the formation of SPD Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, or P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiometabolic, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting. We had a net payable to SPD of $5.2 million as of March 31, 2016 and $1.2 million as of December 31, 2015. The $5.2 million net payable balance as of March 31, 2016 is net of a receivable of approximately $1.4 million for costs incurred in connection with our 2008 SPD-related restructuring plans. The $1.2 million net payable balance as of December 31, 2015 is net of a receivable of approximately $1.5 million for costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $8.6 million and $8.9 million as of March 31, 2016 and December 31, 2015, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the formation of the joint venture have been classified as other receivables within prepaid and other current assets on our consolidated balance sheets in the amounts of $6.6 million and $7.8 million as of March 31, 2016 and December 31, 2015, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $17.7 million and $19.5 million during the three months ended March 31, 2016 and 2015, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.2 million and $0.3 million during the three months ended March 31, 2016 and 2015, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying consolidated statements of operations. Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. We defer our profit on products sold to SPD until the products are sold through to the customer. As a result of these related transactions, we have recorded $7.5 million and $9.9 million of trade receivables which are included in accounts receivable on our consolidated balance sheets as of March 31, 2016 and December 31, 2015, respectively, and $26.9 million and $23.6 million of trade accounts payable which are included in accounts payable on our consolidated balance sheets as of March 31, 2016 and December 31, 2015, respectively. The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption March 31, 2016 December 31, 2015 Accounts receivable, net of allowances $ 7,486 $ 9,873 Prepaid expenses and other current assets $ 6,577 $ 6,602 Other non-current assets $ 8,637 $ 8,895 Accounts payable $ 26,882 $ 24,887 As previously disclosed, SPD is currently involved in civil litigation brought by a competitor in the United States with respect to the advertising of one of SPD’s products in the United States. During 2015, SPD appealed the district court’s injunction with respect to sales and advertising of such product, which was based on a finding that SPD violated certain laws with respect to the advertising of such product. The appellate court has issued a stay of the injunction, pending the outcome of the appeal. A ruling on the appeal is expected in the near future. In addition, a class action lawsuit has been initiated against SPD in the United States District Court for the Central District of California, alleging violations of certain laws in connection with the sales and advertising of one of SPD’s products which claims are based on similar grounds as those at issue in the litigation described above in this paragraph. SPD has moved to dismiss the class action lawsuit on the ground, among others, that the claims pleaded are preempted by federal law. A decision on the motion is expected shortly. There may be additional lawsuits against SPD or us relating to this matter in the future. The ultimate resolution of these matters is not known at this time, nor is the potential impact they may have on SPD or us, including whether any such resolution or any damages imposed by either court would have a material adverse impact on SPD and, ultimately, by virtue of our 50% interest in SPD, on our financial position or results of operations. (b) Entrustment Loan Arrangement with SPD Shanghai Our subsidiary Alere (Shanghai) Diagnostics Co., Ltd., or Alere Shanghai, and SPD’s subsidiary SPD Trading (Shanghai) Co., Ltd., or SPD Shanghai, entered into an entrustment loan arrangement for a maximum of CNY 23 million (approximately $3.6 million at March 31, 2016), in order to finance the latter’s short-term working capital needs, with the Royal Bank of Scotland (China) Co., Ltd. Shanghai Branch, or RBS. The agreement governs the setting up of an Entrustment Loan Account with RBS, into which Alere Shanghai deposits certain monies. This restricted cash account provides a guarantee to RBS of amounts borrowed from RBS by SPD Shanghai. The Alere Shanghai RBS account is recorded as restricted cash on our balance sheet and amounted to $3.6 million at March 31, 2016. (c) TechLab We have an equity method investment in TechLab, Inc., or TechLab, a company that provides diagnostic testing products used by physicians and other health care customers to diagnose, treat, and monitor intestinal diseases and other medical conditions. We own approximately 49% of Techlab. We have also entered into an exclusive distributor agreement with Techlab. This agreement grants us the global distribution rights to Techlab’s products with certain exceptions. We had trade payables owed to Techlab of $1.8 million and $3.2 million as of March 31, 2016 and December 31, 2015, respectively. We made product purchases from Techlab of $4.6 million and $4.4 million during the three months ended March 31, 2016 and 2015, respectively.

Other Arrangements

Other Arrangements	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Arrangements	(16) Other Arrangements In September 2014, we entered into a contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, to develop diagnostic countermeasures for pandemic influenza. Under the terms of the 3.5 year contract, BARDA has agreed to provide up to $12.9 million to us to support the development of a rapid, molecular, low-cost influenza diagnostic device with PCR-like performance at the point of care. The project is designed to help support future preparedness and medical response to an influenza pandemic. Funding from BARDA is subject to successful completion of various interim feasibility and development milestones as defined in the agreement. For the three months ended March 31, 2016 and 2015, we had incurred $0.7 million and $0.5 million, respectively, of qualified expenditures under the contract, for which we had received cash reimbursement from BARDA in the amount of $0.3 million and $0.3 million, respectively, and $0.4 million and $0.1 million were recorded as receivables as of March 31, 2016 and 2015, respectively. Reimbursements of qualified expenditures under this contract are recorded as a reduction of our related qualified research and development expenditures. In February 2013, we entered into an agreement with the Bill & Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of validated, low-cost, nucleic-acid assays and cartridges for clinical Tuberculosis (TB) detection and drug-resistance testing, and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provided for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. In April 2016, we and the Gates Foundation agreed to mutually terminate this grant and loan agreement and, therefore, there will be no additional grants and no advances will be available under the loan agreement. As of March 31, 2016, we had borrowed no amounts under the Gates Loan Agreement. As of March 31, 2016, we had received approximately $19.7 million in grant-related funding from the Gates Foundation. Grant funds were recorded upon receipt as restricted cash and deferred grant funding, with the deferred grant funding classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures were incurred under the terms of the grant, we used the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended March 31, 2015, we incurred approximately $2.1 million of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses. There were no amounts remaining as restricted cash or deferred grant funding under the February 2013 grant agreement as of March 31, 2016. In addition to the February 2013 grant discussed above, we have also been awarded several smaller grants by the Gates Foundation in the aggregate amount of approximately $2.9 million to support the elimination of malaria. We incurred qualifying expenses totaling approximately $0.2 million and $0.2 million for the three months ended March 31, 2016 and 2015, respectively. As of March 31, 2016, $1.8 million was recorded as restricted cash and deferred grant funding on our accompanying consolidated balance sheet.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(17) Commitments and Contingencies (a) Acquisition-related Contingent Consideration Obligations We have contractual contingent purchase price consideration obligations related to certain of our acquisitions. We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our consolidated statements of operations. Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria. The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 103,048 2016 – 2025 (3) $ 48,800 $ 47,800 $ 199 Epocal (2) February 1, 2013 $ 75,000 $ 47,725 2016 – 2018 3,700 4,700 — Other Various $ 30,373 $ — (4) 2016 5,047 5,244 145 $ 57,547 $ 57,744 $ 344 (1) The terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (4) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric. (b) Legal Proceedings U.S. Securities and Exchange Commission Subpoena On August 28, 2015, we received a subpoena from the SEC which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third parties (including distributors and foreign government officials) in Africa relating to sales to government entities. On January 14, 2016, we received a second subpoena from the SEC in connection with this formal investigation seeking, among other things, additional information related to sales of products and services to end-users in Africa, as well as revenue recognition relating to sales of products and services to end-users in Africa. We have also received, from time to time, requests in connection with the investigation to voluntarily produce additional information to the SEC, including information pertaining to certain other countries in Asia and Latin America. We are cooperating with the SEC and have provided documents in response to the subpoenas and voluntary requests. We are unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it. Department of Justice Grand Jury Subpoena On March 11, 2016, we received a grand jury subpoena from the United States Department of Justice requiring the production of documents relating to, among other things, sales, sales practices and dealings with third parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act. We are cooperating with the Department of Justice and have provided information in response to the subpoena. We are unable to predict when this matter will be resolved or what further action, if any, the Department of Justice may take in connection with it. Securities Class Actions On April 21, 2016, a class action lawsuit captioned Godinez Alere Inc. Breton Alere Inc. We are unable at this time to determine the outcome of this class action lawsuit or our potential liability, if any. Matters Relating to our San Diego Facility On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in a Form FDA 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection did not meet the threshold of significance requiring regulatory action, but that formal close-out of the October 2012 warning letter could not occur until after a future inspection. In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the OIG and are responding to the investigation, which is ongoing. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. INRatio Class Actions On May 26, 2016, a class action lawsuit captioned Dina Andren and Sidney Bludman v. Alere Inc et al. J.E, J.D., and all others similarly situated v. Alere Inc., Alere San Diego, Inc. and Alere Home Monitoring, Inc., Dina Andren and Sidney Bludman J.E, J.D., and all others similarly situated Andren We are unable, at this time, to determine the outcome of these class action lawsuits or our potential liability, if any. Claims in the Ordinary Course and Other Matters We are also party to certain other legal proceedings and other governmental investigations, or are requested to provide information in connection with such proceedings or investigations. For example, in December 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. In addition, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians. We are cooperating with these investigations and are providing documents in response to both subpoenas. We and our subsidiary, Arriva Medical, LLC, are also in the process of responding to Civil Investigative Demands, or CIDs, the most recent of which was received in July 2016, from the United States Attorney for the Middle District of Tennessee in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The CIDs request patient and insurance billing and medical records, records related to interactions with third parties, and correspondence relating to the same, dating back to January 2010. We are cooperating with the investigation and are providing documents responsive to the CIDs. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on Alere or its subsidiaries. We have received, from time to time, additional subpoenas and requests for information from the United States Department of Justice, other federal government agencies and state attorneys general, and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. For example, in May 2016, we received a subpoena from the U.S. Attorney for the District of New Jersey, which seeks various documents related to the accuracy, reliability and performance of the INRatio System, including documents relating to prior interactions with the FDA and others regarding the system. Our diabetes, toxicology and patient self-testing businesses are subject to audit and claims for reimbursement brought in the ordinary course by private third-party payers, including health insurers, Zone Program Integrity Contractors, or ZPICs, and Medicare Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support or claims relating to the medical necessity of certain testing and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error. Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, and we expect that this will continue to be the case in the future. For example, several individuals have filed suits against us alleging personal injury claims in connection with the use of our INRatio products (which are in addition to the class action suits described above). Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could adversely impact our business, results of operations, financial condition, and cash flows.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	(18) Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt on or before the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. Please also see Note 3, Summary of Significant Accounting Policies Recently Issued Standards In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements. Recently Adopted Standards In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Interest —Imputation of Interest (Subtopic 835-30) — Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting), In June 2014, the FASB issued ASU No. 2014-12, Compensation — Stock Compensation (Topic 718) — Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. Effective March 31, 2016, we adopted ASU 2014-12. The adoption did not have a significant impact on our consolidated financial statements.

Equity Investments

Equity Investments	3 Months Ended
	Mar. 31, 2016
Equity Method Investments and Joint Ventures [Abstract]
Equity Investments	(19) Equity Investments We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments—Equity Method and Joint Ventures, (a) SPD We recorded earnings of $4.6 million and $3.6 million during the three months ended March 31, 2016 and 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our 50% share of SPD’s net income for the respective periods and elimination of intercompany profit in inventory related to sales from Alere to SPD which is reflected in SPD’s net income. (b) TechLab We recorded earnings of $0.5 million and $0.4 million during the three months ended March 31, 2016 and 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. As of March 31, 2016, we continued to meet the held for sale criteria with respect to our 49% investment in TechLab. We intend to use all or a portion of the proceeds from any sale of this investment to fund our working capital, operations, research and development or repay a portion of our outstanding indebtedness. Accordingly, we have classified our investment in TechLab in assets held for sale – non-current in our consolidated balance sheet as of March 31, 2016. Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended March 31, Combined Condensed Results of Operations: 2016 2015 Net revenue $ 53,434 $ 47,857 Gross profit $ 36,219 $ 33,271 Net income after taxes $ 10,141 $ 8,057 Combined Condensed Balance Sheet: March 31, 2016 December 31, 2015 Current assets $ 90,258 $ 71,542 Non-current assets 29,445 30,802 Total assets $ 119,703 $ 102,344 Current liabilities $ 47,009 $ 37,609 Non-current liabilities 5,033 5,157 Total liabilities $ 52,042 $ 42,766

Provision (Benefit) for Income

Provision (Benefit) for Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Provision (Benefit) for Income Taxes	(21) Provision (Benefit) for Income Taxes The benefit for income taxes decreased by $ 7.7 million to $0.2 million for three months ended March 31, 2016 from $7.9 million for the three months ended March 31, 2015. The effective tax rate for the three months ended March 31, 2016 and 2015, was 1% and 43%, respectively. The Company determines its estimated annual effective tax rate at the end of each interim period based on full-year forecasted pre-tax income and facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income at the end of each interim period. The tax effect of significant unusual items is reflected in the period in which they occur. Our annual effective tax rate is calculated based on forecasted income (loss) across various jurisdictions, and can change based on the mix of jurisdictional income (loss). The difference between the estimated annual effective tax rate and the U.S. federal statutory rate of 35% is primarily attributable to a (100)% impact of the forecasted jurisdictional mix of income and foreign rate differential offset by a 37% impact for the entities with losses which are not benefited, 21% impact from non-deductible stock compensation, and 8% impact for non-deductible transaction costs and other items.

Guarantor Financial Information

Guarantor Financial Information	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information	(22) Guarantor Financial Information Our 7.25% senior notes due 2018, our 6.5% senior subordinated notes due 2020 and our 6.375% senior subordinated notes due 2023 are guaranteed, and before their redemption on October 1, 2015, our 8.625% senior subordinated notes due 2018 were guaranteed, by certain of our consolidated 100% owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of March 31, 2016 and December 31, 2015, the related statements of operations, statements of comprehensive income and statements of cash flows for the three months ended March 31, 2016 and 2015, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting. We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. We have reclassified $32.1 million and $34.1 million of debt issuance costs from Other non-current assets to long-term debt, net of current portion on our balance sheet at March 31, 2016 and December 31, 2015, respectively, as described in Note 18 Recent Accounting Pronouncements As discussed in Note 2 Revision to Previously Reported Consolidated Financial Statements The following schedules reconcile the amounts as previously reported in our consolidating financial statements to the corresponding revised amounts: Three Months Ended March 31, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 328,462 $ (2,170 ) $ 326,292 Cost of net revenue $ 188,036 $ (896 ) $ 187,140 Income (loss) from continuing operations before benefit for income taxes $ 4,916 $ (2,371 ) $ 2,545 Provision (benefit) for income taxes $ 1,820 $ (1,069 ) $ 751 Income (loss) from continuing operations $ 3,096 $ (1,302 ) $ 1,794 Three Months Ended March 31, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 343,359 $ 6,909 $ 350,268 Cost of net revenue $ 192,485 $ 2,405 $ 194,890 Income from continuing operations before benefit for income taxes $ 77,164 $ 4,504 $ 81,668 Provision for income taxes $ 9,715 $ 2,002 $ 11,717 Income from continuing operations $ 71,017 $ 2,502 $ 73,519 CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2016 (in thousands) Guarantor Non-Guarantor Issuer Subsidiaries Subsidiaries Eliminations Consolidated Net product sales $ — $ 224,380 $ 296,837 $ (61,446 ) $ 459,771 Services revenue — 104,484 11,225 — 115,709 Net product sales and services revenue — 328,864 308,062 (61,446 ) 575,480 License and royalty revenue — 2,920 2,558 (2,749 ) 2,729 Net revenue — 331,784 310,620 (64,195 ) 578,209 Cost of net product sales 114 124,758 165,982 (53,393 ) 237,461 Cost of services revenue — 72,495 8,040 (7,435 ) 73,100 Cost of net product sales and services revenue 114 197,253 174,022 (60,828 ) 310,561 Cost of license and royalty revenue — 17 4,123 (2,749 ) 1,391 Cost of net revenue 114 197,270 178,145 (63,577 ) 311,952 Gross profit (loss) (114 ) 134,514 132,475 (618 ) 266,257 Operating expenses: Research and development 4,134 14,459 8,469 — 27,062 Sales and marketing 1,336 54,465 44,012 — 99,813 General and administrative 44,615 33,186 37,155 — 114,956 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (50,199 ) 32,404 46,649 (618 ) 28,236 Interest expense, including amortization of original issue discounts and deferred financing costs (41,087 ) (2,652 ) (3,067 ) 4,700 (42,106 ) Other income (expense), net 1,988 2,502 (1,139 ) (4,700 ) (1,349 ) Income (loss) before provision (benefit) for income taxes (89,298 ) 32,254 42,443 (618 ) (15,219 ) Provision (benefit) for income taxes (54 ) 250 (404 ) — (208 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (89,244 ) 32,004 42,847 (618 ) (15,011 ) Equity in earnings of subsidiaries, net of tax 78,586 — — (78,586 ) — Equity earnings of unconsolidated entities, net of tax 681 — 4,581 (228 ) 5,034 Net income (loss) (9,977 ) 32,004 47,428 (79,432 ) (9,977 ) Less: Net income attributable to non-controlling interests — — 103 — 103 Net income (loss) attributable to Alere Inc. and Subsidiaries (9,977 ) 32,004 47,325 (79,432 ) (10,080 ) Preferred stock dividends (5,309 ) — — — (5,309 ) Net income (loss) available to common stockholders $ (15,286 ) $ 32,004 $ 47,325 $ (79,432 ) $ (15,389 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2015 (in thousands) Guarantor Non-Guarantor Issuer Subsidiaries Subsidiaries Eliminations Consolidated Net product sales $ — $ 215,038 $ 330,106 $ (60,806 ) $ 484,338 Services revenue — 108,057 15,799 — 123,856 Net product sales and services revenue — 323,095 345,905 (60,806 ) 608,194 License and royalty revenue — 3,197 4,363 (2,862 ) 4,698 Net revenue — 326,292 350,268 (63,668 ) 612,892 Cost of net product sales 416 112,295 182,406 (55,016 ) 240,101 Cost of services revenue 50 74,037 8,440 (6,901 ) 75,626 Cost of net product sales and services revenue 466 186,332 190,846 (61,917 ) 315,727 Cost of license and royalty revenue (40 ) 808 4,044 (2,862 ) 1,950 Cost of net revenue 426 187,140 194,890 (64,779 ) 317,677 Gross profit (loss) (426 ) 139,152 155,378 1,111 295,215 Operating expenses: Research and development 2,302 14,919 10,795 — 28,016 Sales and marketing 1,260 53,227 54,592 — 109,079 General and administrative 20,523 37,770 34,398 — 92,691 Impairment and (gain) loss on dispositions, net 36,523 30,608 (32,339 ) — 34,792 Operating income (loss) (61,034 ) 2,628 87,932 1,111 30,637 Interest expense, including amortization of original issue discounts and deferred financing costs (46,098 ) (3,285 ) (4,043 ) 6,995 (46,431 ) Other income (expense), net 3,647 3,202 (2,221 ) (6,995 ) (2,367 ) Income (loss) from continuing operations before provision (benefit) for income taxes (103,485 ) 2,545 81,668 1,111 (18,161 ) Provision (benefit) for income taxes (20,667 ) 751 11,717 346 (7,853 ) Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (82,818 ) 1,794 69,951 765 (10,308 ) Equity in earnings of subsidiaries, net of tax 74,133 — — (74,133 ) — Equity earnings of unconsolidated entities, net of tax 424 — 3,568 (33 ) 3,959 Income (loss) from continuing operations (8,261 ) 1,794 73,519 (73,401 ) (6,349 ) Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income (loss) 210,428 (118 ) 73,519 (73,401 ) 210,428 Less: Net income attributable to non-controlling interests — — 88 — 88 Net income (loss) attributable to Alere Inc. and Subsidiaries 210,428 (118 ) 73,431 (73,401 ) 210,340 Preferred stock dividends (5,250 ) — — — (5,250 ) Net income (loss) available to common stockholders $ 205,178 $ (118 ) $ 73,431 $ (73,401 ) $ 205,090 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2016 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (9,977 ) $ 32,004 $ 47,428 $ (79,432 ) $ (9,977 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 115 (129 ) 22,207 — 22,193 Minimum pension liability adjustment — — 155 — 155 Other comprehensive income (loss), before tax 115 (129 ) 22,362 — 22,348 Income tax benefit related to items of other comprehensive income — — — — — Other comprehensive income (loss), net of tax 115 (129 ) 22,362 — 22,348 Comprehensive income (loss) (9,862 ) 31,875 69,790 (79,432 ) 12,371 Less: Comprehensive income attributable to non-controlling interests — — 103 — 103 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (9,862 ) $ 31,875 $ 69,687 $ (79,432 ) $ 12,268 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2015 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ 210,428 $ (118 ) $ 73,519 $ (73,401 ) $ 210,428 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (657 ) (572 ) (79,113 ) — (80,342 ) Minimum pension liability adjustment — — (1,382 ) — (1,382 ) Other comprehensive loss, before tax (657 ) (572 ) (80,495 ) — (81,724 ) Income tax benefit related to items of other comprehensive income — — — — — Other comprehensive loss, net of tax (657 ) (572 ) (80,495 ) — (81,724 ) Comprehensive income (loss) 209,771 (690 ) (6,976 ) (73,401 ) 128,704 Less: Comprehensive income attributable to non-controlling interests — — 88 — 88 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 209,771 $ (690 ) $ (7,064 ) $ (73,401 ) $ 128,616 CONSOLIDATING BALANCE SHEET March 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 97,071 $ 4,482 $ 389,110 $ — $ 490,663 Restricted cash 1,763 — 4,403 — 6,166 Marketable securities — 71 — — 71 Accounts receivable, net of allowances — 200,537 258,755 — 459,292 Inventories, net — 171,739 204,256 (25,064 ) 350,931 Deferred tax assets (52,409 ) 31,285 23,244 (2,120 ) — Prepaid expenses and other current assets 8,726 25,789 103,276 6,578 144,369 Intercompany receivables 186,846 766,023 129,311 (1,082,180 ) — Total current assets 241,997 1,199,926 1,112,355 (1,102,786 ) 1,451,492 Property, plant and equipment, net 30,124 225,834 191,373 (2,113 ) 445,218 Goodwill — 1,823,647 1,016,045 — 2,839,692 Other intangible assets with indefinite lives — 7,608 21,211 (59 ) 28,760 Finite-lived intangible assets, net 2,873 596,886 365,913 (3,039 ) 962,633 Restricted cash — — 43,388 — 43,388 Other non-current assets 794 2,227 15,414 (508 ) 17,927 Investments in subsidiaries 3,399,545 158,195 57,650 (3,615,390 ) — Investments in unconsolidated entities 687 14,765 43,069 16,223 74,744 Deferred tax assets (14,079 ) 12 30,191 — 16,124 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 11,813 — — — 11,813 Intercompany notes receivables 1,878,821 708,709 5,900 (2,593,430 ) — Total assets $ 5,556,092 $ 4,737,809 $ 2,902,509 $ (7,301,102 ) $ 5,895,308 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 190,073 $ — $ 2,971 $ — $ 193,044 Current portion of capital lease obligations — 2,106 1,942 — 4,048 Accounts payable 12,288 70,302 83,210 — 165,800 Accrued expenses and other current liabilities (546,246 ) 646,418 213,609 2,214 315,995 Intercompany payables 688,995 186,318 206,867 (1,082,180 ) — Total current liabilities 345,110 905,144 508,599 (1,079,966 ) 678,887 Long-term liabilities: Long-term debt, net of current portion 2,777,081 — 46,573 — 2,823,654 Capital lease obligations, net of current portion — 1,636 6,018 — 7,654 Deferred tax liabilities (158,407 ) 250,394 52,414 82 144,483 Other long-term liabilities 15,329 59,504 81,517 (508 ) 155,842 Intercompany notes payables 496,556 1,165,042 931,832 (2,593,430 ) — Total long-term liabilities 3,130,559 1,476,576 1,118,354 (2,593,856 ) 3,131,633 Total stockholders’ equity 2,080,423 2,356,089 1,271,191 (3,627,280 ) 2,080,423 Non-controlling interests — — 4,365 — 4,365 Total equity 2,080,423 2,356,089 1,275,556 (3,627,280 ) 2,084,788 Total liabilities and equity $ 5,556,092 $ 4,737,809 $ 2,902,509 $ (7,301,102 ) $ 5,895,308 CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 Restricted cash 1,250 — 4,444 — 5,694 Marketable securities — 164 — — 164 Accounts receivable, net of allowances — 192,591 253,242 — 445,833 Inventories, net — 173,383 194,192 (20,574 ) 347,001 Deferred tax assets (52,410 ) 31,285 23,244 (2,119 ) — Prepaid expenses and other current assets 7,575 27,095 110,961 6,602 152,233 Assets held for sale — current — — 4,165 — 4,165 Intercompany receivables 620,838 812,957 50,691 (1,484,486 ) — Total current assets 716,406 1,258,625 982,836 (1,500,577 ) 1,457,290 Property, plant and equipment, net 31,384 228,065 188,084 (1,494 ) 446,039 Goodwill — 1,823,919 1,012,996 — 2,836,915 Other intangible assets with indefinite lives — 7,638 20,531 (59 ) 28,110 Finite-lived intangible assets, net 2,951 627,269 370,261 (3,200 ) 997,281 Restricted cash — — 43,228 — 43,228 Other non-current assets 804 2,340 15,380 (446 ) 18,078 Investments in subsidiaries 3,294,857 158,195 57,650 (3,510,702 ) — Investments in unconsolidated entities 502 14,764 37,947 12,120 65,333 Deferred tax assets (14,078 ) (14 ) 28,085 — 13,993 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 13,337 — — — 13,337 Intercompany notes receivables 1,905,188 672,032 6,900 (2,584,120 ) — Total assets $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 197,084 $ — $ 2,908 $ — $ 199,992 Current portion of capital lease obligations — 2,018 1,944 — 3,962 Accounts payable 15,981 76,890 102,881 — 195,752 Accrued expenses and other current liabilities (554,350 ) 650,632 225,944 2,239 324,465 Liabilities related to assets held for sale — current — — 363 — 363 Intercompany payables 1,122,042 249,553 112,891 (1,484,486 ) — Total current liabilities 780,757 979,093 446,931 (1,482,247 ) 724,534 Long-term liabilities: Long-term debt, net of current portion 2,784,913 — 46,253 — 2,831,166 Capital lease obligations, net of current portion — 840 6,341 — 7,181 Deferred tax liabilities (157,708 ) 250,495 54,749 82 147,618 Other long-term liabilities 14,962 59,309 80,369 (447 ) 154,193 Intercompany notes payables 477,779 1,181,168 925,173 (2,584,120 ) — Total long-term liabilities 3,119,946 1,491,812 1,112,885 (2,584,485 ) 3,140,158 Total stockholders’ equity 2,054,165 2,321,928 1,199,818 (3,521,746 ) 2,054,165 Non-controlling interests — — 4,264 — 4,264 Total equity 2,054,165 2,321,928 1,204,082 (3,521,746 ) 2,058,429 Total liabilities and equity $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121 CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (9,977 ) $ 32,004 $ 47,428 $ (79,432 ) $ (9,977 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (78,586 ) — — 78,586 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 2,188 4 44 — 2,236 Depreciation and amortization 2,203 45,691 23,722 888 72,504 Non-cash stock-based compensation expense 5,069 2,287 2,246 — 9,602 Impairment of inventory — — 1,349 — 1,349 Impairment of long-lived assets — 608 — — 608 Loss on sale of fixed assets 15 8 300 — 323 Equity earnings of unconsolidated entities, net of tax (681 ) — (4,581 ) 228 (5,034 ) Deferred income taxes — (100 ) (6,712 ) — (6,812 ) Loss related to impairment and net (gain) loss on dispositions — — (3,810 ) — (3,810 ) Other non-cash items 105 303 2,088 — 2,496 Non-cash change in fair value of contingent purchase price consideration (1,000 ) 1,199 (57 ) — 142 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (7,875 ) (1,324 ) — (9,199 ) Inventories, net — (6,681 ) (7,196 ) (270 ) (14,147 ) Prepaid expenses and other current assets (1,137 ) 1,514 (6,198 ) 25 (5,796 ) Accounts payable (3,694 ) (6,773 ) (21,075 ) — (31,542 ) Accrued expenses and other current liabilities 9,892 (2,703 ) (14,577 ) (25 ) (7,413 ) Other non-current liabilities (616 ) (870 ) 1,562 (62 ) 14 Cash paid for contingent consideration (143 ) — — — (143 ) Intercompany payable (receivable) 46,244 (69,205 ) 22,961 — — Net cash provided by (used in) operating activities (30,118 ) (10,589 ) 36,170 (62 ) (4,599 ) Cash Flows from Investing Activities: (Increase) decrease in restricted cash (513 ) — 77 — (436 ) Purchases of property, plant and equipment (841 ) (5,615 ) (8,048 ) — (14,504 ) Proceeds from sale of property, plant and equipment — 40 572 — 612 Cash received from (used in) dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,945 ) — (5,945 ) Cash received from sales of marketable securities — 93 — — 93 Cash received from equity method investments 2,205 — — — 2,205 Cash paid for investments (184 ) — — — (184 ) (Increase) decrease in other assets (64 ) (98 ) (440 ) 62 (540 ) Net cash provided by (used in) investing activities (734 ) (5,580 ) 9,023 62 2,771 Cash Flows from Financing Activities: Cash paid for financing costs (1 ) — — — (1 ) Cash paid for contingent purchase price consideration — — (145 ) — (145 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — — — 11,124 Proceeds from issuance of long-term debt — — 325 — 325 Payments on long-term debt (17,030 ) — (245 ) — (17,275 ) Net payments under revolving credit facilities — — (127 ) — (127 ) Cash paid for dividends (5,323 ) — — — (5,323 ) Principal payments on capital lease obligations — (659 ) (448 ) — (1,107 ) Net cash used in financing activities (11,230 ) (659 ) (640 ) — (12,529 ) Foreign exchange effect on cash and cash equivalents — 160 2,660 — 2,820 Net increase (decrease) in cash and cash equivalents (42,082 ) (16,668 ) 47,213 — (11,537 ) Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 97,071 $ 4,482 $ 389,110 $ — $ 490,663 CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ 210,428 $ (118 ) $ 73,519 $ (73,401 ) $ 210,428 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income (loss) from continuing operations (8,261 ) 1,794 73,519 (73,401 ) (6,349 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (74,133 ) — — 74,133 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 3,917 7 22 — 3,946 Depreciation and amortization 1,650 42,097 30,654 13 74,414 Non-cash stock-based compensation expense 2,435 1,239 1,475 — 5,149 Impairment of inventory — 133 (55 ) — 78 Impairment of long-lived assets — 28 (97 ) — (69 ) Loss on disposition of fixed assets — 1,346 45 — 1,391 Equity earnings of unconsolidated entities, net of tax (424 ) — (3,568 ) 33 (3,959 ) Deferred income taxes 9 (22,090 ) 318 345 (21,418 ) Loss related to impairment and net (gain) on dispositions 36,523 30,608 (32,339 ) — 34,792 Other non-cash items 1,686 (749 ) 7,245 (1 ) 8,181 Non-cash change in fair value of contingent purchase price consideration 300 171 (14,506 ) — (14,035 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 4,728 (16,483 ) — (11,755 ) Inventories, net — (14,699 ) (13,693 ) (1,313 ) (29,705 ) Prepaid expenses and other current assets (4,680 ) 13,671 15,179 (5,190 ) 18,980 Accounts payable (7,637 ) (470 ) (10,541 ) — (18,648 ) Accrued expenses and other current liabilities (1,681 ) 13,668 (18,881 ) 5,612 (1,282 ) Other non-current liabilities (5,624 ) (191 ) (1,060 ) (473 ) (7,348 ) Cash paid for contingent purchase price consideration (3,641 ) — (13 ) — (3,654 ) Intercompany payable (receivable) 49,312 (57,097 ) 7,784 1 — Net cash provided by (used in) continuing operations (10,249 ) 14,194 25,005 (241 ) 28,709 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities (10,249 ) 14,512 25,005 (241 ) 29,027 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 1,919 — (1,848 ) — 71 Purchases of property, plant and equipment (3,274 ) (10,154 ) (12,409 ) 190 (25,647 ) Proceeds from sale of property, plant and equipment — — 808 — 808 Cash received from (used in) disposition, net of cash divested 587,637 (8,584 ) 2,132 — 581,185 Cash received from sales of marketable securities — 86 — — 86 Decrease in other assets 348 362 152 51 913 Net cash provided by (used in) continuing operations 586,630 (18,290 ) (11,165 ) 241 557,416 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 586,630 (18,499 ) (11,165 ) 241 557,207 Cash Flows from Financing Activities: Cash paid for financing costs (59 ) — — — (59 ) Cash paid for contingent purchase price consideration (3,953 ) — (743 ) — (4,696 ) Proceeds from issuance of common stock, net of issuance costs 34,632 — — — 34,632 Proceeds from issuance of long-term debt — — 15 — 15 Payments on short-term debt — — (321 ) — (321 ) Payments on long-term debt (463,000 ) — (11 ) — (463,011 ) Net payments under revolving credit facilities (127,000 ) — (50 ) — (127,050 ) Cash paid for dividends (5,323 ) — — — (5,323 ) Principal payments on capital lease obligations — (627 ) (857 ) — (1,484 ) Net cash used in continuing operations (564,703 ) (627 ) (1,967 ) — (567,297 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash used in financing activities (564,703 ) (703 ) (1,967 ) — (567,373 ) Foreign exchange effect on cash and cash equivalents — (207 ) (5,920 ) — (6,127 ) Net increase (decrease) in cash and cash equivalents 11,678 (4,897 ) 5,953 — 12,734 Cash and cash equivalents, beginning of period - continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period - discontinued operations — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 13,827 $ 87,557 $ 313,111 $ — $ 414,495

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	(23) Subsequent Events Amendments and waivers under Credit Agreement and note indentures As further described in Note 12 above, in April 2016 we entered into an amendment to our Credit Agreement, and in May 2016 we obtained consents to amend the indentures governing certain of our senior and senior subordinated notes. We expect to seek an amendment to the Credit Agreement On August 10, 2016, we filed a Form 12b-25 disclosing that we were unable to file our Quarterly Report on Form 10-Q for the three months ended June 30, 2016 within the prescribed time period without unreasonable effort or expense. As of the date hereof, we are seeking an amendment to the Credit Agreement that, if approved by the lenders, would provide an extension of the date by which we must deliver to the Administrative Agents (as defined in the Credit Agreement): (i) the financial statements for the three months ended June 30, 2016 and related deliverables to September 13, 2016 and (ii) the financial statements for the three months ended March 31, 2016 and related deliverables to August 25, 2016 and waive certain related potential defaults and Events of Default (as defined in the Credit Agreement). Maturity of our 3.0% convertible senior subordinated notes Our 3% convertible senior subordinated notes matured on May 15, 2016. Based on the price of our common stock on the date of maturity, we paid all outstanding principal and accrued interest owing under such notes in cash. The aggregate amount paid to the noteholders at maturity was approximately $152.0 million, consisting of $125.0 million in cash drawn under our revolving credit facility plus $27.0 million of cash available on such date INRatio ® In July 2016 we announced that we will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 PT/INR Monitoring System. We are currently working with the FDA on implementing the product withdrawal and eventual product discontinuation. In December 2014, we initiated a voluntary correction to inform users of the Alere INRatio and INRatio2 PT/INR Monitoring Systems that patients with certain medical conditions should not be tested with the systems. We proactively reported these device concerns to the FDA and began conducting a thorough investigation into these events. Over the course of the past two years, Alere invested in the research and development of software enhancements intended to address the potential, in certain cases, of the system to deliver a result that differs from that of another measurement method. We submitted the software enhancements to the FDA at the end of 2015. The FDA notified us that it believes that our studies do not adequately demonstrate the effectiveness of the software modification and advised us to submit a proposed plan to voluntarily remove the INRatio ® In light of this input from the FDA and our business considerations, in July 2016 we determined to voluntarily remove the INRatio systems from the market. Due to the fact that the circumstances giving rise to the voluntary withdrawal in the United States and related action outside the U.S. existed as of December 31, 2015, certain charges incurred in connection with the withdrawal were recorded in the fourth quarter of 2015. Specifically, we recorded a charge of approximately $38 million in the year ended December 31, 2015, related to impairment of inventory and production equipment and estimated costs of removing our INRatio and INRatio2 from the market. As of March 31, 2016, $16.0 million of the estimated costs of removing INRatio and INRatio 2 from the market were included in accrued expenses. Additionally, our decision to withdraw the INRatio and INRatio2 PT/INR Monitoring Systems impacted the useful life assumptions of certain tangible and intangible assets. As a result of this change in estimate, we recorded approximately $4.1 million of accelerated amortization of intangible assets and approximately $0.7 million of accelerated depreciation of tangible assets in the three months ended March 31, 2016. Finally, during the remainder of fiscal year 2016 we expect to incur approximately $12.3 million of accelerated amortization, approximately $2.4 million of accelerated depreciation, and $2.0 million of other one-time cash expenditures.

Basis of Presentation of Fina29

Basis of Presentation of Financial Information (Policies)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2015 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on August 8, 2016. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015. Certain amounts presented may not recalculate directly, due to rounding.
Cash and Cash Equivalents	We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At March 31, 2016, our cash equivalents consisted of money market funds.

Revision of Previously Report30

Revision of Previously Reported Consolidated Financial Statements (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Restated and Revised Consolidated Statement of Operations	The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts: Three Months Ended March 31, 2015 Revised Consolidated Statement of Operations (in thousands) As Previously Revision As Net product sales $ 479,599 $ 4,739 $ 484,338 Net product sales and services revenue $ 603,455 $ 4,739 $ 608,194 Net revenue $ 608,153 $ 4,739 $ 612,892 Cost of net product sales $ 238,637 $ 1,464 $ 240,101 Cost of services revenue $ 75,581 $ 45 $ 75,626 Cost of net product sales and services revenue $ 314,218 $ 1,509 $ 315,727 Cost of net revenue $ 316,168 $ 1,509 $ 317,677 Gross profit $ 291,985 $ 3,230 $ 295,215 Operating income $ 27,407 $ 3,230 $ 30,637 Other income (expense), net $ (1,270 ) $ (1,097 ) $ (2,367 ) Loss from continuing operations before benefit for income taxes $ (20,294 ) $ 2,133 $ (18,161 ) Benefit (provision) for income taxes $ (8,786 ) $ 933 $ (7,853 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax $ (11,508 ) $ 1,200 $ (10,308 ) Income (loss) from continuing operations $ (7,549 ) $ 1,200 $ (6,349 ) Net income $ 209,228 $ 1,200 $ 210,428 Net income attributable to Alere Inc. and Subsidiaries $ 209,140 $ 1,200 $ 210,340 Net income available to common stockholders $ 203,890 $ 1,200 $ 205,090 Basic and diluted net income (loss) per common share: Net income (loss) from continuing operations $ (0.15 ) $ 0.01 $ (0.14 ) Basic and diluted net income per common share: Net income per common share $ 2.42 $ 0.01 $ 2.43
Restated and Revised Consolidated Statement of Comprehensive Loss	Three Months Ended March 31, 2015 Revised Consolidated Statement of Comprehensive Income (in thousands) As Previously Revision As Revised Net income $ 209,228 $ 1,200 $ 210,428 Comprehensive income $ 127,504 $ 1,200 $ 128,704 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 127,416 $ 1,200 $ 128,616
Restated and Revised Consolidated Statement of Cash Flows	Three Months Ended March 31, 2015 Revised Consolidated Statement of Cash Flows (In thousands) As Previously Revision As Net income $ 209,228 $ 1,200 $ 210,428 Loss from continuing operations $ (7,549 ) $ 1,200 $ (6,349 ) Depreciation and amortization $ 74,368 $ 46 $ 74,414 Deferred income taxes $ (20,349 ) $ (1,069 ) $ (21,418 ) Accounts receivable, net $ (16,881 ) $ 5,126 $ (11,755 ) Inventories, net $ (31,168 ) $ 1,463 $ (29,705 ) Accrued expenses and other current liabilities $ 5,484 $ (6,766 ) $ (1,282 ) Other non-current liabilities $ (7,997 ) $ 649 $ (7,348 ) Net cash provided by operating activities $ 28,378 $ 649 $ 29,027 Excess tax benefits on exercised stock options $ 649 $ (649 ) $ — Net cash used in financing activities $ (566,724 ) $ (649 ) $ (567,373 )

Discontinued Operations, Impa31

Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net (Tables)	3 Months Ended
	Mar. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Summarized Financial Information Related to Health Management Business	The following summarized financial information related to the health management business has been segregated from continuing operations and reported as discontinued operations in our consolidated statement of operations for the three months ended March 31, 2015. The results are as follows (in thousands): Three Months Ended Net revenue $ 7,373 Cost of net revenue (4,413 ) Sales and marketing (996 ) General and administrative (5,001 ) Interest expense (9 ) Other income (expense), net 160 Gain on disposal 366,191 Income from discontinued operations before provision for income taxes 363,305 Provision for income taxes 146,528 Income from discontinued operations, net of tax $ 216,777

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventories are Stated at Lower of Cost (First In, First Out) or Market	Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): March 31, 2016 December 31, 2015 Raw materials $ 125,111 $ 130,171 Work-in-process 75,625 69,178 Finished goods 150,195 147,652 $ 350,931 $ 347,001

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense	We recorded stock-based compensation expense in our consolidated statements of operations for the three months ended March 31, 2016 and 2015 as follows (in thousands): Three Months Ended March 31, 2016 2015 Cost of net revenue $ 479 $ 253 Research and development 398 324 Sales and marketing 1,925 1,094 General and administrative 6,800 3,478 9,602 5,149 Benefit for income taxes — (2,373 ) Stock-based compensation, net of tax $ 9,602 $ 2,776

Net Income (Loss) per Common 34

Net Income (Loss) per Common Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Common Share	The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2016 and 2015 (in thousands, except per share amounts): Three Months Ended March 31, 2016 2015 Basic and diluted net income (loss) per common share: Numerator: Loss from continuing operations $ (9,977 ) $ (6,349 ) Preferred stock dividends (5,309 ) (5,250 ) Loss from continuing operations attributable to common shares (15,286 ) (11,599 ) Less: Net income attributable to non-controlling 103 88 Loss from continuing operations attributable to Alere Inc. and Subsidiaries (15,389 ) (11,687 ) Income from discontinued operations — 216,777 Net income (loss) available to common stockholders $ (15,389 ) $ 205,090 Denominator: Weighted-average common shares outstanding – basic and diluted 86,646 84,338 Basic and diluted net income (loss) per common share: Loss from continuing operations attributable to Alere Inc. and Subsidiaries $ (0.18 ) $ (0.14 ) Income from discontinued operations — 2.57 Basic and diluted net income (loss) per common share $ (0.18 ) $ 2.43
Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share	The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands): Three Months Ended March 31, 2016 2015 Denominator: Options to purchase shares of common stock 7,378 7,882 Warrants — 4 Conversion shares related to 3% convertible senior subordinated notes 3,411 3,411 Conversion shares related to subordinated convertible promissory notes — 27 Conversion shares related to Series B convertible preferred stock 10,239 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 21,028 21,563

Stockholders' Equity and Non-35

Stockholders' Equity and Non-controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity	A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the three months ended March 31, 2016 is provided below (in thousands): Three Months Ended March 31, 2016 Total Stockholders’ Equity Non- Interests Total Equity Equity, beginning of period $ 2,054,165 $ 4,264 $ 2,058,429 Issuance of common stock under employee compensation plans 11,123 — 11,123 Net issuance of common stock to settle taxes on restricted stock units (1,412 ) — (1,412 ) Preferred stock dividends (5,323 ) — (5,323 ) Stock-based compensation expense 9,602 — 9,602 Excess tax benefits on exercised stock options — — — Other adjustments — (2 ) (2 ) Net income (loss) (10,080 ) 103 (9,977 ) Total other comprehensive income (loss) 22,348 — 22,348 Equity, end of period $ 2,080,423 $ 4,365 $ 2,084,788

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Summary of Aggregate Purchase Price Allocation	A summary of the preliminary fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,053 Intangible assets 4,220 Total assets acquired $ 7,759 Current liabilities $ 1,301 Total liabilities assumed $ 1,301 Net assets acquired $ 6,458 Cash paid $ 6,458
Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives	The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective preliminary fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- average Useful Life Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete agreements 570 3.0 years Total intangible assets $ 4,220

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2016
Restructuring and Related Activities [Abstract]
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income	The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three months ended March 31, 2016 and 2015 (in thousands): Three Months Ended March 31, Statement of Operations Caption 2016 2015 Cost of net revenue 1,267 1,502 Research and development 1,920 493 Sales and marketing 650 1,383 General and administrative 3,826 892 Total operating expenses 7,663 4,270 Interest expense, including amortization of original issue discounts and deferred financing costs 5 7 Total charges 7,668 4,277
Restructuring Activities Related to Restructuring Plans	The following table summarizes the restructuring activities related to our 2016 restructuring plans, in addition to our earlier restructuring plans as disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, for the three months ended March 31, 2016 and 2015 and since inception of these restructuring plans (in thousands): Three Months Ended March 31, Since 2016 2015 Inception Professional Diagnostics Severance-related costs $ 3,091 $ 2,800 $ 41,078 Facility and transition costs 981 1,426 12,649 Other exit costs 5 7 827 Cash charges 4,077 4,233 54,554 Fixed asset and inventory impairments 398 9 16,351 Other non-cash charges 213 — 2,195 Total professional diagnostics charges $ 4,688 $ 4,242 $ 73,100 Corporate and Other Severance-related costs $ 15 $ 42 $ 4,292 Facility and transition costs 2,965 (7 ) 14,287 Total corporate and other charges $ 2,980 $ 35 $ 18,579 Total restructuring charges $ 7,668 $ 4,277 $ 91,679
Cash Activity for Restructuring Reserves	The following table summarizes our restructuring reserves related to the plans described above, of which $6.1 million is included in accrued expenses and other current liabilities and $1.0 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 3,106 3,946 5 7,057 Payments (1,904 ) (1,897 ) (36 ) (3,837 ) Currency adjustments 45 37 — 82 Balance, March 31, 2016 $ 2,880 $ 4,052 $ 149 $ 7,081

Long-term Debt (Tables)

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt Balances Outstanding	We had the following long-term debt balances outstanding (in thousands): March 31, 2016 December 31, 2015 A term loans (1)(2) $ 568,955 $ 575,746 B term loans (1)(2) 963,656 965,740 7.25% Senior notes (2) 446,689 446,320 6.5% Senior subordinated notes (2) 419,533 419,209 6.375% Senior subordinated notes (2) 418,362 418,133 3% Convertible senior subordinated notes (3) 149,960 149,839 Other lines of credit 22 136 Other 49,521 56,035 3,016,698 3,031,158 Less: Short-term debt and current portion of long-term debt (193,044 ) (199,992 ) Long-term debt $ 2,823,654 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 12, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, this Quarterly Report on Form 10-Q and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing such notes. (3) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015 and March 31, 2016, as these notes matured (and were fully paid and discharged) in May 2016.
Long-Term Debt Interest Expense	In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three months ended March 31, 2016 and 2015 as follows (in thousands): Three Months Ended March 31, 2016 2015 Secured credit facility (1) $ 17,043 $ — Prior credit facility (2) — 19,462 7.25% Senior notes 8,524 8,524 6.375% Senior subordinated notes 7,003 — 6.5% Senior subordinated notes 7,231 7,233 8.625% Senior subordinated notes — 9,273 3% Convertible senior subordinated notes 1,244 1,246 Other 1,060 693 $ 42,105 $ 46,431 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. For the three months ended March 31, 2016 and 2015, the amounts include $0.0 million and $0.4 million, respectively, related to the amortization of fees paid for certain debt modifications.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description March 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 71 $ 71 $ — $ — Total assets $ 71 $ 71 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,547 $ — $ — $ 57,547 Total liabilities $ 57,547 $ — $ — $ 57,547 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17 for additional information on the valuation of our contingent consideration obligations.
Changes in Fair Value of Contingent Consideration Obligations	Changes in the fair value of our Level 3 contingent consideration obligations during the three months ended March 31, 2016 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (344 ) Fair value adjustments 143 Foreign currency adjustments 4 Fair value of contingent consideration obligations, March 31, 2016 $ 57,547

Financial Information by Segm40

Financial Information by Segment (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss)	Segment information for the three months ended March 31, 2016 and 2015 is as follows (in thousands): Professional Consumer Corporate Total Three Months Ended March 31, 2016: Net revenue $ 560,768 $ 17,442 $ — $ 578,209 Operating income (loss) $ 82,679 $ 167 $ (54,610 ) $ 28,236 Gain on dispositions, net $ 3,810 $ — $ — $ 3,810 Depreciation and amortization $ 68,832 $ 1,499 $ 2,173 $ 72,504 Restructuring charges $ 4,688 $ — $ 2,980 $ 7,668 Stock-based compensation $ — $ — $ 9,602 $ 9,602 Three Months Ended March 31, 2015: Net revenue $ 590,924 $ 21,968 $ — $ 612,892 Operating income (loss) $ 89,543 $ 2,204 $ (61,110 ) $ 30,637 Impairment and (gain) loss on dispositions, net $ (1,731 ) $ — $ 36,523 $ 34,792 Depreciation and amortization $ 72,469 $ 711 $ 1,234 $ 74,414 Restructuring charges $ 4,235 $ — $ 35 $ 4,270 Stock-based compensation $ — $ — $ 5,149 $ 5,149 Assets: As of March 31, 2016 $ 5,627,777 $ 178,699 $ 88,832 $ 5,895,308 As of December 31, 2015 $ 5,619,901 $ 172,551 $ 130,669 $ 5,923,121
Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services	The following table summarizes our net revenue from the professional diagnostics reporting segment by groups of similar products and services for the three months ended March 31, 2016 and 2015 (in thousands): Three Months Ended March 31, 2016 2015 Cardiometabolic $ 194,577 $ 200,936 Infectious disease 183,234 185,402 Toxicology 146,783 148,756 Other 33,444 51,132 Total professional diagnostics net product sales and services revenue 558,038 586,226 License and royalty revenue 2,730 4,698 Total professional diagnostics net revenue $ 560,768 $ 590,924

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Balances with SPD within Consolidated Balance Sheets	The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption March 31, 2016 December 31, 2015 Accounts receivable, net of allowances $ 7,486 $ 9,873 Prepaid expenses and other current assets $ 6,577 $ 6,602 Other non-current assets $ 8,637 $ 8,895 Accounts payable $ 26,882 $ 24,887

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions	The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 103,048 2016 – 2025 (3) $ 48,800 $ 47,800 $ 199 Epocal (2) February 1, 2013 $ 75,000 $ 47,725 2016 – 2018 3,700 4,700 — Other Various $ 30,373 $ — (4) 2016 5,047 5,244 145 $ 57,547 $ 57,744 $ 344 (1) The terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (4) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric.

Guarantor Financial Informati43

Guarantor Financial Information (Tables)	3 Months Ended
	Mar. 31, 2016
Financial Information Combined Condensed Results of Operations	CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2016 (in thousands) Guarantor Non-Guarantor Issuer Subsidiaries Subsidiaries Eliminations Consolidated Net product sales $ — $ 224,380 $ 296,837 $ (61,446 ) $ 459,771 Services revenue — 104,484 11,225 — 115,709 Net product sales and services revenue — 328,864 308,062 (61,446 ) 575,480 License and royalty revenue — 2,920 2,558 (2,749 ) 2,729 Net revenue — 331,784 310,620 (64,195 ) 578,209 Cost of net product sales 114 124,758 165,982 (53,393 ) 237,461 Cost of services revenue — 72,495 8,040 (7,435 ) 73,100 Cost of net product sales and services revenue 114 197,253 174,022 (60,828 ) 310,561 Cost of license and royalty revenue — 17 4,123 (2,749 ) 1,391 Cost of net revenue 114 197,270 178,145 (63,577 ) 311,952 Gross profit (loss) (114 ) 134,514 132,475 (618 ) 266,257 Operating expenses: Research and development 4,134 14,459 8,469 — 27,062 Sales and marketing 1,336 54,465 44,012 — 99,813 General and administrative 44,615 33,186 37,155 — 114,956 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (50,199 ) 32,404 46,649 (618 ) 28,236 Interest expense, including amortization of original issue discounts and deferred financing costs (41,087 ) (2,652 ) (3,067 ) 4,700 (42,106 ) Other income (expense), net 1,988 2,502 (1,139 ) (4,700 ) (1,349 ) Income (loss) before provision (benefit) for income taxes (89,298 ) 32,254 42,443 (618 ) (15,219 ) Provision (benefit) for income taxes (54 ) 250 (404 ) — (208 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (89,244 ) 32,004 42,847 (618 ) (15,011 ) Equity in earnings of subsidiaries, net of tax 78,586 — — (78,586 ) — Equity earnings of unconsolidated entities, net of tax 681 — 4,581 (228 ) 5,034 Net income (loss) (9,977 ) 32,004 47,428 (79,432 ) (9,977 ) Less: Net income attributable to non-controlling interests — — 103 — 103 Net income (loss) attributable to Alere Inc. and Subsidiaries (9,977 ) 32,004 47,325 (79,432 ) (10,080 ) Preferred stock dividends (5,309 ) — — — (5,309 ) Net income (loss) available to common stockholders $ (15,286 ) $ 32,004 $ 47,325 $ (79,432 ) $ (15,389 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended March 31, 2015 (in thousands) Guarantor Non-Guarantor Issuer Subsidiaries Subsidiaries Eliminations Consolidated Net product sales $ — $ 215,038 $ 330,106 $ (60,806 ) $ 484,338 Services revenue — 108,057 15,799 — 123,856 Net product sales and services revenue — 323,095 345,905 (60,806 ) 608,194 License and royalty revenue — 3,197 4,363 (2,862 ) 4,698 Net revenue — 326,292 350,268 (63,668 ) 612,892 Cost of net product sales 416 112,295 182,406 (55,016 ) 240,101 Cost of services revenue 50 74,037 8,440 (6,901 ) 75,626 Cost of net product sales and services revenue 466 186,332 190,846 (61,917 ) 315,727 Cost of license and royalty revenue (40 ) 808 4,044 (2,862 ) 1,950 Cost of net revenue 426 187,140 194,890 (64,779 ) 317,677 Gross profit (loss) (426 ) 139,152 155,378 1,111 295,215 Operating expenses: Research and development 2,302 14,919 10,795 — 28,016 Sales and marketing 1,260 53,227 54,592 — 109,079 General and administrative 20,523 37,770 34,398 — 92,691 Impairment and (gain) loss on dispositions, net 36,523 30,608 (32,339 ) — 34,792 Operating income (loss) (61,034 ) 2,628 87,932 1,111 30,637 Interest expense, including amortization of original issue discounts and deferred financing costs (46,098 ) (3,285 ) (4,043 ) 6,995 (46,431 ) Other income (expense), net 3,647 3,202 (2,221 ) (6,995 ) (2,367 ) Income (loss) from continuing operations before provision (benefit) for income taxes (103,485 ) 2,545 81,668 1,111 (18,161 ) Provision (benefit) for income taxes (20,667 ) 751 11,717 346 (7,853 ) Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (82,818 ) 1,794 69,951 765 (10,308 ) Equity in earnings of subsidiaries, net of tax 74,133 — — (74,133 ) — Equity earnings of unconsolidated entities, net of tax 424 — 3,568 (33 ) 3,959 Income (loss) from continuing operations (8,261 ) 1,794 73,519 (73,401 ) (6,349 ) Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income (loss) 210,428 (118 ) 73,519 (73,401 ) 210,428 Less: Net income attributable to non-controlling interests — — 88 — 88 Net income (loss) attributable to Alere Inc. and Subsidiaries 210,428 (118 ) 73,431 (73,401 ) 210,340 Preferred stock dividends (5,250 ) — — — (5,250 ) Net income (loss) available to common stockholders $ 205,178 $ (118 ) $ 73,431 $ (73,401 ) $ 205,090
Financial Information Combined Condensed Balance Sheet	CONSOLIDATING BALANCE SHEET March 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 97,071 $ 4,482 $ 389,110 $ — $ 490,663 Restricted cash 1,763 — 4,403 — 6,166 Marketable securities — 71 — — 71 Accounts receivable, net of allowances — 200,537 258,755 — 459,292 Inventories, net — 171,739 204,256 (25,064 ) 350,931 Deferred tax assets (52,409 ) 31,285 23,244 (2,120 ) — Prepaid expenses and other current assets 8,726 25,789 103,276 6,578 144,369 Intercompany receivables 186,846 766,023 129,311 (1,082,180 ) — Total current assets 241,997 1,199,926 1,112,355 (1,102,786 ) 1,451,492 Property, plant and equipment, net 30,124 225,834 191,373 (2,113 ) 445,218 Goodwill — 1,823,647 1,016,045 — 2,839,692 Other intangible assets with indefinite lives — 7,608 21,211 (59 ) 28,760 Finite-lived intangible assets, net 2,873 596,886 365,913 (3,039 ) 962,633 Restricted cash — — 43,388 — 43,388 Other non-current assets 794 2,227 15,414 (508 ) 17,927 Investments in subsidiaries 3,399,545 158,195 57,650 (3,615,390 ) — Investments in unconsolidated entities 687 14,765 43,069 16,223 74,744 Deferred tax assets (14,079 ) 12 30,191 — 16,124 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 11,813 — — — 11,813 Intercompany notes receivables 1,878,821 708,709 5,900 (2,593,430 ) — Total assets $ 5,556,092 $ 4,737,809 $ 2,902,509 $ (7,301,102 ) $ 5,895,308 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 190,073 $ — $ 2,971 $ — $ 193,044 Current portion of capital lease obligations — 2,106 1,942 — 4,048 Accounts payable 12,288 70,302 83,210 — 165,800 Accrued expenses and other current liabilities (546,246 ) 646,418 213,609 2,214 315,995 Intercompany payables 688,995 186,318 206,867 (1,082,180 ) — Total current liabilities 345,110 905,144 508,599 (1,079,966 ) 678,887 Long-term liabilities: Long-term debt, net of current portion 2,777,081 — 46,573 — 2,823,654 Capital lease obligations, net of current portion — 1,636 6,018 — 7,654 Deferred tax liabilities (158,407 ) 250,394 52,414 82 144,483 Other long-term liabilities 15,329 59,504 81,517 (508 ) 155,842 Intercompany notes payables 496,556 1,165,042 931,832 (2,593,430 ) — Total long-term liabilities 3,130,559 1,476,576 1,118,354 (2,593,856 ) 3,131,633 Total stockholders’ equity 2,080,423 2,356,089 1,271,191 (3,627,280 ) 2,080,423 Non-controlling interests — — 4,365 — 4,365 Total equity 2,080,423 2,356,089 1,275,556 (3,627,280 ) 2,084,788 Total liabilities and equity $ 5,556,092 $ 4,737,809 $ 2,902,509 $ (7,301,102 ) $ 5,895,308 CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 Restricted cash 1,250 — 4,444 — 5,694 Marketable securities — 164 — — 164 Accounts receivable, net of allowances — 192,591 253,242 — 445,833 Inventories, net — 173,383 194,192 (20,574 ) 347,001 Deferred tax assets (52,410 ) 31,285 23,244 (2,119 ) — Prepaid expenses and other current assets 7,575 27,095 110,961 6,602 152,233 Assets held for sale — current — — 4,165 — 4,165 Intercompany receivables 620,838 812,957 50,691 (1,484,486 ) — Total current assets 716,406 1,258,625 982,836 (1,500,577 ) 1,457,290 Property, plant and equipment, net 31,384 228,065 188,084 (1,494 ) 446,039 Goodwill — 1,823,919 1,012,996 — 2,836,915 Other intangible assets with indefinite lives — 7,638 20,531 (59 ) 28,110 Finite-lived intangible assets, net 2,951 627,269 370,261 (3,200 ) 997,281 Restricted cash — — 43,228 — 43,228 Other non-current assets 804 2,340 15,380 (446 ) 18,078 Investments in subsidiaries 3,294,857 158,195 57,650 (3,510,702 ) — Investments in unconsolidated entities 502 14,764 37,947 12,120 65,333 Deferred tax assets (14,078 ) (14 ) 28,085 — 13,993 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 13,337 — — — 13,337 Intercompany notes receivables 1,905,188 672,032 6,900 (2,584,120 ) — Total assets $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 197,084 $ — $ 2,908 $ — $ 199,992 Current portion of capital lease obligations — 2,018 1,944 — 3,962 Accounts payable 15,981 76,890 102,881 — 195,752 Accrued expenses and other current liabilities (554,350 ) 650,632 225,944 2,239 324,465 Liabilities related to assets held for sale — current — — 363 — 363 Intercompany payables 1,122,042 249,553 112,891 (1,484,486 ) — Total current liabilities 780,757 979,093 446,931 (1,482,247 ) 724,534 Long-term liabilities: Long-term debt, net of current portion 2,784,913 — 46,253 — 2,831,166 Capital lease obligations, net of current portion — 840 6,341 — 7,181 Deferred tax liabilities (157,708 ) 250,495 54,749 82 147,618 Other long-term liabilities 14,962 59,309 80,369 (447 ) 154,193 Intercompany notes payables 477,779 1,181,168 925,173 (2,584,120 ) — Total long-term liabilities 3,119,946 1,491,812 1,112,885 (2,584,485 ) 3,140,158 Total stockholders’ equity 2,054,165 2,321,928 1,199,818 (3,521,746 ) 2,054,165 Non-controlling interests — — 4,264 — 4,264 Total equity 2,054,165 2,321,928 1,204,082 (3,521,746 ) 2,058,429 Total liabilities and equity $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121
Schedule of Reconciliation of Previously Reported and Revised Consolidating Financial Statements	The following schedules reconcile the amounts as previously reported in our consolidating financial statements to the corresponding revised amounts: Three Months Ended March 31, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 328,462 $ (2,170 ) $ 326,292 Cost of net revenue $ 188,036 $ (896 ) $ 187,140 Income (loss) from continuing operations before benefit for income taxes $ 4,916 $ (2,371 ) $ 2,545 Provision (benefit) for income taxes $ 1,820 $ (1,069 ) $ 751 Income (loss) from continuing operations $ 3,096 $ (1,302 ) $ 1,794 Three Months Ended March 31, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 343,359 $ 6,909 $ 350,268 Cost of net revenue $ 192,485 $ 2,405 $ 194,890 Income from continuing operations before benefit for income taxes $ 77,164 $ 4,504 $ 81,668 Provision for income taxes $ 9,715 $ 2,002 $ 11,717 Income from continuing operations $ 71,017 $ 2,502 $ 73,519
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss)	CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2016 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (9,977 ) $ 32,004 $ 47,428 $ (79,432 ) $ (9,977 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 115 (129 ) 22,207 — 22,193 Minimum pension liability adjustment — — 155 — 155 Other comprehensive income (loss), before tax 115 (129 ) 22,362 — 22,348 Income tax benefit related to items of other comprehensive income — — — — — Other comprehensive income (loss), net of tax 115 (129 ) 22,362 — 22,348 Comprehensive income (loss) (9,862 ) 31,875 69,790 (79,432 ) 12,371 Less: Comprehensive income attributable to non-controlling interests — — 103 — 103 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (9,862 ) $ 31,875 $ 69,687 $ (79,432 ) $ 12,268 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended March 31, 2015 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ 210,428 $ (118 ) $ 73,519 $ (73,401 ) $ 210,428 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (657 ) (572 ) (79,113 ) — (80,342 ) Minimum pension liability adjustment — — (1,382 ) — (1,382 ) Other comprehensive loss, before tax (657 ) (572 ) (80,495 ) — (81,724 ) Income tax benefit related to items of other comprehensive income — — — — — Other comprehensive loss, net of tax (657 ) (572 ) (80,495 ) — (81,724 ) Comprehensive income (loss) 209,771 (690 ) (6,976 ) (73,401 ) 128,704 Less: Comprehensive income attributable to non-controlling interests — — 88 — 88 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 209,771 $ (690 ) $ (7,064 ) $ (73,401 ) $ 128,616
Guarantor Financial Information Consolidating Statement of Cash Flows	CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (9,977 ) $ 32,004 $ 47,428 $ (79,432 ) $ (9,977 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (78,586 ) — — 78,586 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 2,188 4 44 — 2,236 Depreciation and amortization 2,203 45,691 23,722 888 72,504 Non-cash stock-based compensation expense 5,069 2,287 2,246 — 9,602 Impairment of inventory — — 1,349 — 1,349 Impairment of long-lived assets — 608 — — 608 Loss on sale of fixed assets 15 8 300 — 323 Equity earnings of unconsolidated entities, net of tax (681 ) — (4,581 ) 228 (5,034 ) Deferred income taxes — (100 ) (6,712 ) — (6,812 ) Loss related to impairment and net (gain) loss on dispositions — — (3,810 ) — (3,810 ) Other non-cash items 105 303 2,088 — 2,496 Non-cash change in fair value of contingent purchase price consideration (1,000 ) 1,199 (57 ) — 142 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (7,875 ) (1,324 ) — (9,199 ) Inventories, net — (6,681 ) (7,196 ) (270 ) (14,147 ) Prepaid expenses and other current assets (1,137 ) 1,514 (6,198 ) 25 (5,796 ) Accounts payable (3,694 ) (6,773 ) (21,075 ) — (31,542 ) Accrued expenses and other current liabilities 9,892 (2,703 ) (14,577 ) (25 ) (7,413 ) Other non-current liabilities (616 ) (870 ) 1,562 (62 ) 14 Cash paid for contingent consideration (143 ) — — — (143 ) Intercompany payable (receivable) 46,244 (69,205 ) 22,961 — — Net cash provided by (used in) operating activities (30,118 ) (10,589 ) 36,170 (62 ) (4,599 ) Cash Flows from Investing Activities: (Increase) decrease in restricted cash (513 ) — 77 — (436 ) Purchases of property, plant and equipment (841 ) (5,615 ) (8,048 ) — (14,504 ) Proceeds from sale of property, plant and equipment — 40 572 — 612 Cash received from (used in) dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,945 ) — (5,945 ) Cash received from sales of marketable securities — 93 — — 93 Cash received from equity method investments 2,205 — — — 2,205 Cash paid for investments (184 ) — — — (184 ) (Increase) decrease in other assets (64 ) (98 ) (440 ) 62 (540 ) Net cash provided by (used in) investing activities (734 ) (5,580 ) 9,023 62 2,771 Cash Flows from Financing Activities: Cash paid for financing costs (1 ) — — — (1 ) Cash paid for contingent purchase price consideration — — (145 ) — (145 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — — — 11,124 Proceeds from issuance of long-term debt — — 325 — 325 Payments on long-term debt (17,030 ) — (245 ) — (17,275 ) Net payments under revolving credit facilities — — (127 ) — (127 ) Cash paid for dividends (5,323 ) — — — (5,323 ) Principal payments on capital lease obligations — (659 ) (448 ) — (1,107 ) Net cash used in financing activities (11,230 ) (659 ) (640 ) — (12,529 ) Foreign exchange effect on cash and cash equivalents — 160 2,660 — 2,820 Net increase (decrease) in cash and cash equivalents (42,082 ) (16,668 ) 47,213 — (11,537 ) Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 97,071 $ 4,482 $ 389,110 $ — $ 490,663 CONSOLIDATING STATEMENT OF CASH FLOWS For the Three Months Ended March 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ 210,428 $ (118 ) $ 73,519 $ (73,401 ) $ 210,428 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income (loss) from continuing operations (8,261 ) 1,794 73,519 (73,401 ) (6,349 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (74,133 ) — — 74,133 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 3,917 7 22 — 3,946 Depreciation and amortization 1,650 42,097 30,654 13 74,414 Non-cash stock-based compensation expense 2,435 1,239 1,475 — 5,149 Impairment of inventory — 133 (55 ) — 78 Impairment of long-lived assets — 28 (97 ) — (69 ) Loss on disposition of fixed assets — 1,346 45 — 1,391 Equity earnings of unconsolidated entities, net of tax (424 ) — (3,568 ) 33 (3,959 ) Deferred income taxes 9 (22,090 ) 318 345 (21,418 ) Loss related to impairment and net (gain) on dispositions 36,523 30,608 (32,339 ) — 34,792 Other non-cash items 1,686 (749 ) 7,245 (1 ) 8,181 Non-cash change in fair value of contingent purchase price consideration 300 171 (14,506 ) — (14,035 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 4,728 (16,483 ) — (11,755 ) Inventories, net — (14,699 ) (13,693 ) (1,313 ) (29,705 ) Prepaid expenses and other current assets (4,680 ) 13,671 15,179 (5,190 ) 18,980 Accounts payable (7,637 ) (470 ) (10,541 ) — (18,648 ) Accrued expenses and other current liabilities (1,681 ) 13,668 (18,881 ) 5,612 (1,282 ) Other non-current liabilities (5,624 ) (191 ) (1,060 ) (473 ) (7,348 ) Cash paid for contingent purchase price consideration (3,641 ) — (13 ) — (3,654 ) Intercompany payable (receivable) 49,312 (57,097 ) 7,784 1 — Net cash provided by (used in) continuing operations (10,249 ) 14,194 25,005 (241 ) 28,709 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities (10,249 ) 14,512 25,005 (241 ) 29,027 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 1,919 — (1,848 ) — 71 Purchases of property, plant and equipment (3,274 ) (10,154 ) (12,409 ) 190 (25,647 ) Proceeds from sale of property, plant and equipment — — 808 — 808 Cash received from (used in) disposition, net of cash divested 587,637 (8,584 ) 2,132 — 581,185 Cash received from sales of marketable securities — 86 — — 86 Decrease in other assets 348 362 152 51 913 Net cash provided by (used in) continuing operations 586,630 (18,290 ) (11,165 ) 241 557,416 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 586,630 (18,499 ) (11,165 ) 241 557,207 Cash Flows from Financing Activities: Cash paid for financing costs (59 ) — — — (59 ) Cash paid for contingent purchase price consideration (3,953 ) — (743 ) — (4,696 ) Proceeds from issuance of common stock, net of issuance costs 34,632 — — — 34,632 Proceeds from issuance of long-term debt — — 15 — 15 Payments on short-term debt — — (321 ) — (321 ) Payments on long-term debt (463,000 ) — (11 ) — (463,011 ) Net payments under revolving credit facilities (127,000 ) — (50 ) — (127,050 ) Cash paid for dividends (5,323 ) — — — (5,323 ) Principal payments on capital lease obligations — (627 ) (857 ) — (1,484 ) Net cash used in continuing operations (564,703 ) (627 ) (1,967 ) — (567,297 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash used in financing activities (564,703 ) (703 ) (1,967 ) — (567,373 ) Foreign exchange effect on cash and cash equivalents — (207 ) (5,920 ) — (6,127 ) Net increase (decrease) in cash and cash equivalents 11,678 (4,897 ) 5,953 — 12,734 Cash and cash equivalents, beginning of period - continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period - discontinued operations — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 13,827 $ 87,557 $ 313,111 $ — $ 414,495
Swiss Precision Diagnostics And Techlab [Member]
Financial Information Combined Condensed Results of Operations	Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended March 31, Combined Condensed Results of Operations: 2016 2015 Net revenue $ 53,434 $ 47,857 Gross profit $ 36,219 $ 33,271 Net income after taxes $ 10,141 $ 8,057
Financial Information Combined Condensed Balance Sheet	Combined Condensed Balance Sheet: March 31, 2016 December 31, 2015 Current assets $ 90,258 $ 71,542 Non-current assets 29,445 30,802 Total assets $ 119,703 $ 102,344 Current liabilities $ 47,009 $ 37,609 Non-current liabilities 5,033 5,157 Total liabilities $ 52,042 $ 42,766

Revision of Previously Report44

Revision of Previously Reported Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 578,209	$ 612,892
Cost of net product sales and services revenue	237,461	240,101
Other income (expense), net	$ (1,349)	(2,367)
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		4,739
Cost of net product sales and services revenue		1,464
Other income (expense), net		$ (1,097)

Revision of Previously Report45

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ 459,771	$ 484,338
Net product sales and services revenue	575,480	608,194
Net revenue	578,209	612,892
Cost of net product sales	237,461	240,101
Cost of services revenue	73,100	75,626
Cost of net product sales and services revenue	310,561	315,727
Cost of net revenue	311,952	317,677
Gross profit	266,257	295,215
Operating income	28,236	30,637
Other income (expense), net	(1,349)	(2,367)
Income (loss) before provision (benefit) for income taxes	(15,219)	(18,161)
Benefit (provision) for income taxes	(208)	(7,853)
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(15,011)	(10,308)
Income (loss) from continuing operations	(9,977)	(6,349)
Net income	(9,977)	210,428
Net income attributable to Alere Inc. and Subsidiaries	(10,080)	210,340
Net income available to common stockholders	$ (15,389)	$ 205,090
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted net income (loss) per common share: Net income (loss) from continuing operations	$ (0.18)	$ (0.14)
Basic and diluted net income per common share: Net income per common share	$ (0.18)	$ 2.43
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ 479,599
Net product sales and services revenue		603,455
Net revenue		608,153
Cost of net product sales		238,637
Cost of services revenue		75,581
Cost of net product sales and services revenue		314,218
Cost of net revenue		316,168
Gross profit		291,985
Operating income		27,407
Other income (expense), net		(1,270)
Income (loss) before provision (benefit) for income taxes		(20,294)
Benefit (provision) for income taxes		(8,786)
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax		(11,508)
Income (loss) from continuing operations		(7,549)
Net income		209,228
Net income attributable to Alere Inc. and Subsidiaries		209,140
Net income available to common stockholders		$ 203,890
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted net income (loss) per common share: Net income (loss) from continuing operations		$ (0.15)
Basic and diluted net income per common share: Net income per common share		$ 2.42
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ 4,739
Net product sales and services revenue		4,739
Net revenue		4,739
Cost of net product sales		1,464
Cost of services revenue		45
Cost of net product sales and services revenue		1,509
Cost of net revenue		1,509
Gross profit		3,230
Operating income		3,230
Other income (expense), net		(1,097)
Income (loss) before provision (benefit) for income taxes		2,133
Benefit (provision) for income taxes		933
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax		1,200
Income (loss) from continuing operations		1,200
Net income		1,200
Net income attributable to Alere Inc. and Subsidiaries		1,200
Net income available to common stockholders		$ 1,200
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted net income (loss) per common share: Net income (loss) from continuing operations		$ 0.01
Basic and diluted net income per common share: Net income per common share		$ 0.01

Revision of Previously Report46

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	$ (9,977)	$ 210,428
Comprehensive income	12,371	128,704
Comprehensive income attributable to Alere Inc. and Subsidiaries	$ 12,268	128,616
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		209,228
Comprehensive income		127,504
Comprehensive income attributable to Alere Inc. and Subsidiaries		127,416
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		1,200
Comprehensive income		1,200
Comprehensive income attributable to Alere Inc. and Subsidiaries		$ 1,200

Revision of Previously Report47

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	$ (9,977)	$ 210,428
Loss from continuing operations	(9,977)	(6,349)
Depreciation and amortization	72,504	74,414
Deferred income taxes	(6,812)	(21,418)
Accounts receivable, net	(9,199)	(11,755)
Inventories, net	(14,147)	(29,705)
Accrued expenses and other current liabilities	(7,413)	(1,282)
Other non-current liabilities	14	(7,348)
Net cash provided by operating activities	(4,599)	29,027
Excess tax benefits on exercised stock options		0
Net cash used in financing activities	$ (12,529)	(567,373)
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		209,228
Loss from continuing operations		(7,549)
Depreciation and amortization		74,368
Deferred income taxes		(20,349)
Accounts receivable, net		(16,881)
Inventories, net		(31,168)
Accrued expenses and other current liabilities		5,484
Other non-current liabilities		(7,997)
Net cash provided by operating activities		28,378
Excess tax benefits on exercised stock options		649
Net cash used in financing activities		(566,724)
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		1,200
Loss from continuing operations		1,200
Depreciation and amortization		46
Deferred income taxes		(1,069)
Accounts receivable, net		5,126
Inventories, net		1,463
Accrued expenses and other current liabilities		(6,766)
Other non-current liabilities		649
Net cash provided by operating activities		649
Excess tax benefits on exercised stock options		(649)
Net cash used in financing activities		$ (649)

Merger Agreement - Additional I

Merger Agreement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Jan. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Preferred Stock, par value		$ 0.001	$ 0.001
Merger Agreement [Member]
Business Acquisition [Line Items]
Right to receive cash by each common stockholder	$ 56
Termination fee of agreement	$ 177
Merger Agreement [Member] | Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value	$ 0.001
Merger Agreement [Member] | Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value	$ 0.001

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - Health Management Business [Member] $ in Millions	Jan. 09, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of subsidiary	$ 599.9
Prior Credit Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of senior secured credit facility	$ 575

Discontinued Operations - Summa

Discontinued Operations - Summarized Financial Information Related to Health Management Business (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ 0	$ 216,777
Health Management Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue		7,373
Cost of net revenue		(4,413)
Sales and marketing		(996)
General and administrative		(5,001)
Interest expense		(9)
Other income (expense), net		160
Gain on disposal		366,191
Income from discontinued operations before provision for income taxes		363,305
Provision for income taxes		146,528
Income from discontinued operations, net of tax		$ 216,777

Cash and Cash Equivalents - Add

Cash and Cash Equivalents - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016
Cash and Cash Equivalents [Abstract]
Cash investments maturity period	Three months or less

Inventories - Inventories are S

Inventories - Inventories are Stated at Lower of Cost (First In, First Out) or Market (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 125,111	$ 130,171
Work-in-process	75,625	69,178
Finished goods	150,195	147,652
Inventories, net	$ 350,931	$ 347,001

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 9,602	$ 5,149
Benefit for income taxes	0	(2,373)
Stock-based compensation, net of tax	9,602	2,776
Cost of Net Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	479	253
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	398	324
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,925	1,094
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 6,800	$ 3,478

Net Income (Loss) Per Common 54

Net Income (Loss) Per Common Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Loss from continuing operations	$ (9,977)	$ (6,349)
Preferred stock dividends	(5,309)	(5,250)
Loss from continuing operations attributable to common shares	(15,286)	(11,599)
Less: Net income attributable to non-controlling interest	103	88
Loss from continuing operations attributable to Alere Inc. and Subsidiaries	(15,389)	(11,687)
Income from discontinued operations	0	216,777
Net income (loss) available to common stockholders	$ (15,389)	$ 205,090
Denominator:
Weighted-average common shares outstanding - basic and diluted	86,646	84,338
Basic and diluted net income (loss) per common share:
Loss from continuing operations attributable to Alere Inc. and Subsidiaries	$ (0.18)	$ (0.14)
Income from discontinued operations	0	2.57
Basic and diluted net income (loss) per common share	$ (0.18)	$ 2.43

Net Income (Loss) Per Common 55

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	21,028	21,563
Options to Purchase Shares of Common Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	7,378	7,882
Warrants [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	4
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	3,411	3,411
Conversion Shares Related to Subordinated Convertible Promissory Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	27
Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	10,239	10,239

Net Income (Loss) Per Common 56

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Parenthetical) (Detail)	Mar. 31, 2016	Mar. 31, 2015
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate of debt instrument	3.00%	3.00%

Stockholders' Equity and Non-57

Stockholders' Equity and Non-controlling Interests - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Class of Stock [Line Items]
Preferred stock dividends	$ 5,309	$ 5,250
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock dividends	5,300	5,300
Preferred stock dividends accrued	5,300
Preferred stock dividends cash paid	$ 5,300	$ 5,300

Stockholders' Equity and Non-58

Stockholders' Equity and Non-controlling Interests - Summary of Changes in Stockholders' Equity and Non-controlling Interests Comprising Total Equity (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	$ 2,058,429
Issuance of common stock under employee compensation plans	11,123
Net issuance of common stock to settle taxes on restricted stock units	(1,412)
Preferred stock dividends	(5,323)
Stock-based compensation expense	9,602
Excess tax benefits on exercised stock options	0
Other adjustments	(2)
Net income (loss)	(9,977)	$ 210,428
Total other comprehensive income (loss)	22,348	$ (81,724)
Equity, end of period	2,084,788
Total Stockholders' Equity [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	2,054,165
Issuance of common stock under employee compensation plans	11,123
Net issuance of common stock to settle taxes on restricted stock units	(1,412)
Preferred stock dividends	(5,323)
Stock-based compensation expense	9,602
Excess tax benefits on exercised stock options	0
Other adjustments	0
Net income (loss)	(10,080)
Total other comprehensive income (loss)	22,348
Equity, end of period	2,080,423
Non-controlling Interests [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period	4,264
Issuance of common stock under employee compensation plans	0
Net issuance of common stock to settle taxes on restricted stock units	0
Preferred stock dividends	0
Stock-based compensation expense	0
Excess tax benefits on exercised stock options	0
Other adjustments	(2)
Net income (loss)	103
Total other comprehensive income (loss)	0
Equity, end of period	$ 4,365

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Feb. 11, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,839,692		$ 2,836,915
EDTS [Member]
Business Acquisition [Line Items]
Preliminary aggregate purchase price		$ 6,500
Total revenue related to acquisition	900
Goodwill	$ 2,100

Business Combinations - Summary

Business Combinations - Summary of Aggregate Purchase Price Allocation (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Business Combinations [Abstract]
Current assets	$ 1,371
Property, plant and equipment	115
Goodwill	2,053
Intangible assets	4,220
Total assets acquired	7,759
Current liabilities	1,301
Total liabilities assumed	1,301
Net assets acquired	6,458
Cash paid	$ 6,458

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Finite And Infinite Lived Intangible Assets [Line Items]
Total intangible assets	$ 4,220
Core Technology and Patents [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 540
Weighted-average Useful Life	10 years
Trademarks and Trade Names [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 310
Weighted-average Useful Life	20 years
Customer Relationships [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 2,800
Weighted-average Useful Life	14 years
Non-Competition Agreements [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 570
Weighted-average Useful Life	3 years

Restructuring - Aggregate Charg

Restructuring - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 7,668	$ 4,270
Restructuring charges	7,668	4,277
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5	7
Cost of Net Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,267	1,502
Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,920	493
Sales and Marketing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	650	1,383
General and Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,826	892
Total Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 7,663	$ 4,270

Restructuring - Restructuring A

Restructuring - Restructuring Activities Related to Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		99 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 7,668	$ 4,270
Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,688	4,235
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,980	35
2016 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7,668	4,277	$ 91,679
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,688	4,242	73,100
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,091	2,800	41,078
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	981	1,426	12,649
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,077	4,233	54,554
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	398	9	16,351
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5	7	827
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Non-Cash Recoveries [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	213		2,195
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,980	35	18,579
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	15	42	4,292
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 2,965	$ (7)	$ 14,287

Restructuring - Additional Info

Restructuring - Additional Information (Detail) $ in Millions	Mar. 31, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring reserves included in accrued expenses and other current liabilities	$ 6.1
Restructuring reserves included in other long-term liabilities	1
2016 Restructuring Plans [Member] | Manufacturing Facility [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	3.8
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	3.2
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	$ 5.9

Restructuring - Cash Activity f

Restructuring - Cash Activity for Restructuring Reserves (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Cash charges	$ 7,668	$ 4,270
Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	3,779
Cash charges	7,057
Payments	(3,837)
Currency adjustments	82
Restructuring Reserve, Ending Balance	7,081
Severance-Related Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	1,633
Cash charges	3,106
Payments	(1,904)
Currency adjustments	45
Restructuring Reserve, Ending Balance	2,880
Facility and Transition Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	1,966
Cash charges	3,946
Payments	(1,897)
Currency adjustments	37
Restructuring Reserve, Ending Balance	4,052
Other Exit Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	180
Cash charges	5
Payments	(36)
Currency adjustments	0
Restructuring Reserve, Ending Balance	$ 149

Long-Term Debt - Long-Term Debt

Long-Term Debt - Long-Term Debt Balances Outstanding (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt, Total	$ 3,016,698	$ 3,031,158
Less: Short-term debt and current portion of long-term debt	(193,044)	(199,992)
Long-term debt	2,823,654	2,831,166
A Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	568,955	575,746
B Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	963,656	965,740
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	446,689	446,320
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	419,533	419,209
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	418,362	418,133
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	149,960	149,839
Other Lines of Credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	22	136
Other [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 49,521	$ 56,035

Long-Term Debt - Long-Term De67

Long-Term Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail)	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Description of default under credit agreement		(i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement for and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, this Quarterly Report on Form 10-Q and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing such notes.
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%	3.00%	3.00%
Maturity date	May 31, 2016

Long-Term Debt - Long-Term De68

Long-Term Debt - Long-Term Debt Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 42,105	$ 46,431
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	17,043	0
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	19,462
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	8,524	8,524
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,003	0
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,231	7,233
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	9,273
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	1,244	1,246
Other [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 1,060	$ 693

Long-Term Debt - Long-Term De69

Long-Term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Amortization fee	$ 0	$ 0.4
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	8.625%	8.625%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%	3.00%	3.00%

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Jul. 01, 2016	May 15, 2016	Apr. 22, 2016	Jul. 31, 2016	May 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Repayment of long term debt						$ 17,275,000	$ 463,011,000
Subsequent Events [Member]
Debt Instrument [Line Items]
Rate of aggregate consent fee			0.25%
Amount of aggregate consent fee			$ 4,500,000
Increase in applicable interest rate margin for all loans outstanding	0.25%
Consent aggregate payments per 1,000 aggregate principal amount				$ 15	$ 15
Aggregate payments to note holders				$ 19,200,000	$ 19,200,000
Subsequent Events [Member] | 3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Repayment of long term debt		$ 152,000,000
Subsequent Events [Member] | 3% Convertible Senior Subordinated Notes [Member] | Cash [Member]
Debt Instrument [Line Items]
Repayment of long term debt		27,000,000
Subsequent Events [Member] | 3% Convertible Senior Subordinated Notes [Member] | Secured Credit Facility Revolving Line-Of-Credit [Member]
Debt Instrument [Line Items]
Repayment of long term debt		$ 125,000,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	$ 71	$ 164
Total assets	71	164
Liabilities:
Contingent consideration obligations	57,547	57,744
Total liabilities	57,547	57,744
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	71	164
Total assets	71	164
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	57,547	57,744
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	57,547	57,744
Total liabilities	$ 57,547	$ 57,744

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) - Unobservable Inputs (Level 3) [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration obligations, Beginning balance	$ 57,744
Payments	(344)
Fair value adjustments	143
Foreign currency adjustments	4
Fair value of contingent consideration obligations, Ending balance	$ 57,547

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Billions	Mar. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Estimated fair value of long-term debt	$ 3.1	$ 3
Long-term debt, Total	$ 3	$ 3.1

Financial Information by Segm74

Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net revenue	$ 578,209	$ 612,892
Operating income (loss)	28,236	30,637
Gain on dispositions, net	3,810	(34,792)
Impairment and (gain) loss on dispositions, net	(3,810)	34,792
Depreciation and amortization	72,504	74,414
Restructuring charges	7,668	4,270
Stock-based compensation	9,602	5,149
Assets	5,895,308		$ 5,923,121
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	560,768	590,924
Operating income (loss)	82,679	89,543
Gain on dispositions, net	3,810
Impairment and (gain) loss on dispositions, net		(1,731)
Depreciation and amortization	68,832	72,469
Restructuring charges	4,688	4,235
Stock-based compensation	0	0
Assets	5,627,777		5,619,901
Consumer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	17,442	21,968
Operating income (loss)	167	2,204
Gain on dispositions, net	0
Impairment and (gain) loss on dispositions, net		0
Depreciation and amortization	1,499	711
Restructuring charges	0	0
Stock-based compensation	0	0
Assets	178,699		172,551
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenue	0	0
Operating income (loss)	(54,610)	(61,110)
Gain on dispositions, net	0
Impairment and (gain) loss on dispositions, net		36,523
Depreciation and amortization	2,173	1,234
Restructuring charges	2,980	35
Stock-based compensation	9,602	$ 5,149
Assets	$ 88,832		$ 130,669

Financial Information by Segm75

Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Sales revenue net	$ 575,480	$ 608,194
Total professional diagnostics net product sales and services revenue	115,709	123,856
License and royalty revenue	2,729	4,698
Net revenue	578,209	612,892
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	560,768	590,924
Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Total professional diagnostics net product sales and services revenue	558,038	586,226
License and royalty revenue	2,730	4,698
Net revenue	560,768	590,924
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Cardiometabolic [Member]
Segment Reporting Information [Line Items]
Sales revenue net	194,577	200,936
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Infectious Disease [Member]
Segment Reporting Information [Line Items]
Sales revenue net	183,234	185,402
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Toxicology [Member]
Segment Reporting Information [Line Items]
Sales revenue net	146,783	148,756
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Sales revenue net	$ 33,444	$ 51,132

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Mar. 31, 2016CNY (¥)	May 31, 2007
Related Party Transaction [Line Items]
Restructuring charges	$ 7,668	$ 4,270
SPD [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage	50.00%			50.00%	50.00%
SPD Shanghai [Member]
Related Party Transaction [Line Items]
Restricted cash	$ 3,600
SPD Shanghai [Member] | Maximum [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party	$ 3,600			¥ 23,000,000
TechLab [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage	49.00%			49.00%
Net payable to SPD	$ 1,800		$ 3,200
Purchases from related party	4,600	4,400
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Net payable to SPD	5,200		1,200
Restructuring charges	1,400		1,500
Long-term receivable cost related to restructuring plan	8,600		8,900
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables	6,600		7,800
Trade receivables from SPD	7,500		9,900
Trade payable to SPD	26,900		$ 23,600
SPD Joint Venture [Member] | Sales Revenue Goods [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	17,700	19,500
SPD Joint Venture [Member] | Sales Revenue Services [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	$ 200	$ 300

Related Party Transactions - Re

Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	$ 459,292	$ 445,833
Prepaid expenses and other current assets	144,369	152,233
Other non-current assets	17,927	18,078
Accounts payable	165,800	195,752
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	7,486	9,873
Prepaid expenses and other current assets	6,577	6,602
Other non-current assets	8,637	8,895
Accounts payable	$ 26,882	$ 24,887

Other Arrangements - Additional

Other Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Sep. 30, 2014	Feb. 28, 2013	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Period of contract	3 years 6 months
The amount provided for development of diagnostic device by BARDA as defined in the agreement	$ 12,900,000
Net expenditure incurred under the contract			$ 700,000	$ 500,000
The amount of cash reimbursement received from BARDA			300,000	300,000
Amount of accounts receivables			400,000	100,000
Restricted cash			6,166,000		$ 5,694,000
Gates Foundation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded		$ 21,600,000
Cash received from grant-related funding			19,700,000
Qualified expenditures				2,100,000
Deferred grant funding			0
Restricted cash			0
Excess funds returned			1,800,000
Gates Foundation [Member] | Malaria Program [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded			2,900,000
Qualified expenditures			$ 200,000	$ 200,000
Gates Loan Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Aggregate principal amount of subordinated term loan		$ 20,600,000

Commitments and Contingencies -

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Business Acquisition, Contingent Consideration [Line Items]
Estimated Fair Value	$ 57,547,000	$ 57,744,000
Payments Made During 2016	$ 344,000
TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Mar. 11, 2010
Acquisition Date Fair Value	$ 35,600,000
Maximum Remaining Earn-out Potential	103,048,000
Estimated Fair Value	48,800,000	47,800,000
Payments Made During 2016	$ 199,000
Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Feb. 1, 2013
Acquisition Date Fair Value	$ 75,000,000
Maximum Remaining Earn-out Potential	47,725,000
Estimated Fair Value	3,700,000	4,700,000
Payments Made During 2016	$ 0
Other [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Various
Acquisition Date Fair Value	$ 30,373,000
Maximum Remaining Earn-out Potential	$ 0
Remaining Earn-out Period	2,016
Estimated Fair Value	$ 5,047,000	$ 5,244,000
Payments Made During 2016	$ 145,000
Minimum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,016
Minimum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,016
Maximum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,025
Maximum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,018

Commitments and Contingencies80

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Earn-out period	15 years

Recent Accounting Pronounceme81

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Accounting Standards Update 2015-15 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs	$ 32.1	$ 34.1

Equity Investments - Additional

Equity Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	May 31, 2007
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax	$ 5,034	$ 3,959
SPD [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax	$ 4,600	3,600
Equity method investment ownership percentage	50.00%		50.00%
TechLab [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax	$ 500	$ 400
Equity method investment ownership percentage	49.00%

Equity Investments - Financial

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Results of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Net revenue	$ 53,434	$ 47,857
Gross profit	36,219	33,271
Net income after taxes	$ 10,141	$ 8,057

Equity Investments - Financia84

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Current assets	$ 90,258	$ 71,542
Non-current assets	29,445	30,802
Total assets	119,703	102,344
Current liabilities	47,009	37,609
Non-current liabilities	5,033	5,157
Total liabilities	$ 52,042	$ 42,766

Impairment and (Gain) Loss on D

Impairment and (Gain) Loss on Dispositions, Net - Additional Information (Detail) $ in Thousands, € in Millions	1 Months Ended			3 Months Ended
	Jan. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2015EUR (€)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) from sale of assets				$ 3,810	$ (34,792)
Alere E-Sante [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of business, cash received	$ 8,100
Sale of business, working capital adjustment	200
Sale of business, contingent consideration	$ 1,500
Gain (Loss) on sale of disposal group				$ 3,800
AdnaGen GmbH [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets		$ 4,600
Gain (loss) from sale of assets					(300)
Gesellschaft Fur Patientenhilfe DGP GmbH [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on sale of disposal group					$ (7,500)
Cash proceeds from sale of business		$ 8,200	€ 7.6

Provision (Benefit) for Incom86

Provision (Benefit) for Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Increase in income tax benefit	$ (7,700)
Benefit for income taxes	$ (208)	$ (7,853)
Effective tax rate	1.00%	43.00%
U.S. federal statutory rate	35.00%
Percentage impact of forecasted jurisdictional mix of income and foreign rate differential	(100.00%)
Percentage impact for federal and state R&D tax credit	37.00%
Percentage impact from non-deductible stock compensation	21.00%
Percentage impact of non-deductible transaction costs	8.00%

Guarantor Financial Informati87

Guarantor Financial Information - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Accounting Standards Update 2015-15 [Member]
Debt Instrument [Line Items]
Debt issuance cost	$ 32.1	$ 34.1
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	7.25%	7.25%	7.25%
Maturity year of debt instrument	2,018
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.50%	6.50%	6.50%
Maturity year of debt instrument	2,020
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.375%	6.375%	6.375%
Maturity year of debt instrument	2,023
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	8.625%		8.625%
Maturity year of debt instrument	2,018
Maturity date	Oct. 1, 2015

Guarantor Financial Informati88

Guarantor Financial Information - Revised Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 578,209	$ 612,892
Cost of net revenue	311,952	317,677
Income (loss) from continuing operations before benefit for income taxes	(15,219)	(18,161)
Provision (benefit) for income taxes	(208)	(7,853)
Income (loss) from continuing operations	(9,977)	(6,349)
Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	331,784	326,292
Cost of net revenue	197,270	187,140
Income (loss) from continuing operations before benefit for income taxes	32,254	2,545
Provision (benefit) for income taxes	250	751
Income (loss) from continuing operations		1,794
Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	310,620	350,268
Cost of net revenue	178,145	194,890
Income (loss) from continuing operations before benefit for income taxes	42,443	81,668
Provision (benefit) for income taxes	$ (404)	11,717
Income (loss) from continuing operations		73,519
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		608,153
Cost of net revenue		316,168
Income (loss) from continuing operations before benefit for income taxes		(20,294)
Provision (benefit) for income taxes		(8,786)
Income (loss) from continuing operations		(7,549)
As Previously Reported [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		328,462
Cost of net revenue		188,036
Income (loss) from continuing operations before benefit for income taxes		4,916
Provision (benefit) for income taxes		1,820
Income (loss) from continuing operations		3,096
As Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		343,359
Cost of net revenue		192,485
Income (loss) from continuing operations before benefit for income taxes		77,164
Provision (benefit) for income taxes		9,715
Income (loss) from continuing operations		71,017
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		4,739
Cost of net revenue		1,509
Income (loss) from continuing operations before benefit for income taxes		2,133
Provision (benefit) for income taxes		933
Income (loss) from continuing operations		1,200
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		(2,170)
Cost of net revenue		896
Income (loss) from continuing operations before benefit for income taxes		(2,371)
Provision (benefit) for income taxes		(1,069)
Income (loss) from continuing operations		(1,302)
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		6,909
Cost of net revenue		2,405
Income (loss) from continuing operations before benefit for income taxes		4,504
Provision (benefit) for income taxes		2,002
Income (loss) from continuing operations		$ 2,502

Guarantor Financial Informati89

Guarantor Financial Information - Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Net product sales	$ 459,771	$ 484,338
Services revenue	115,709	123,856
Net product sales and services revenue	575,480	608,194
License and royalty revenue	2,729	4,698
Net revenue	578,209	612,892
Cost of net product sales	237,461	240,101
Cost of services revenue	73,100	75,626
Cost of net product sales and services revenue	310,561	315,727
Cost of license and royalty revenue	1,391	1,950
Cost of net revenue	311,952	317,677
Gross profit (loss)	266,257	295,215
Operating expenses:
Research and development	27,062	28,016
Sales and marketing	99,813	109,079
General and administrative	114,956	92,691
Impairment and (gain) loss on dispositions, net	(3,810)	34,792
Operating income (loss)	28,236	30,637
Interest expense, including amortization of original issue discounts and deferred financing costs	(42,106)	(46,431)
Other income (expense), net	(1,349)	(2,367)
Income (loss) before provision (benefit) for income taxes	(15,219)	(18,161)
Provision (benefit) for income taxes	(208)	(7,853)
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(15,011)	(10,308)
Equity in earnings of subsidiaries, net of tax	0	0
Equity earnings of unconsolidated entities, net of tax	5,034	3,959
Income (loss) from continuing operations	(9,977)	(6,349)
Income (loss) from discontinued operations, net of tax	0	216,777
Net income (loss)	(9,977)	210,428
Less: Net income attributable to non-controlling interests	103	88
Net income (loss) attributable to Alere Inc. and Subsidiaries	(10,080)	210,340
Preferred stock dividends	(5,309)	(5,250)
Net income (loss) available to common stockholders	(15,389)	205,090
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	0	0
Services revenue	0	0
Net product sales and services revenue	0	0
License and royalty revenue	0	0
Net revenue	0	0
Cost of net product sales	114	416
Cost of services revenue	0	50
Cost of net product sales and services revenue	114	466
Cost of license and royalty revenue	0	(40)
Cost of net revenue	114	426
Gross profit (loss)	(114)	(426)
Operating expenses:
Research and development	4,134	2,302
Sales and marketing	1,336	1,260
General and administrative	44,615	20,523
Impairment and (gain) loss on dispositions, net	0	36,523
Operating income (loss)	(50,199)	(61,034)
Interest expense, including amortization of original issue discounts and deferred financing costs	(41,087)	(46,098)
Other income (expense), net	1,988	3,647
Income (loss) before provision (benefit) for income taxes	(89,298)	(103,485)
Provision (benefit) for income taxes	(54)	(20,667)
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(89,244)	(82,818)
Equity in earnings of subsidiaries, net of tax	78,586	74,133
Equity earnings of unconsolidated entities, net of tax	681	424
Income (loss) from continuing operations		(8,261)
Income (loss) from discontinued operations, net of tax		218,689
Net income (loss)	(9,977)	210,428
Less: Net income attributable to non-controlling interests	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(9,977)	210,428
Preferred stock dividends	(5,309)	(5,250)
Net income (loss) available to common stockholders	(15,286)	205,178
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	224,380	215,038
Services revenue	104,484	108,057
Net product sales and services revenue	328,864	323,095
License and royalty revenue	2,920	3,197
Net revenue	331,784	326,292
Cost of net product sales	124,758	112,295
Cost of services revenue	72,495	74,037
Cost of net product sales and services revenue	197,253	186,332
Cost of license and royalty revenue	17	808
Cost of net revenue	197,270	187,140
Gross profit (loss)	134,514	139,152
Operating expenses:
Research and development	14,459	14,919
Sales and marketing	54,465	53,227
General and administrative	33,186	37,770
Impairment and (gain) loss on dispositions, net	0	30,608
Operating income (loss)	32,404	2,628
Interest expense, including amortization of original issue discounts and deferred financing costs	(2,652)	(3,285)
Other income (expense), net	2,502	3,202
Income (loss) before provision (benefit) for income taxes	32,254	2,545
Provision (benefit) for income taxes	250	751
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	32,004	1,794
Equity in earnings of subsidiaries, net of tax	0	0
Equity earnings of unconsolidated entities, net of tax	0	0
Income (loss) from continuing operations		1,794
Income (loss) from discontinued operations, net of tax		(1,912)
Net income (loss)	32,004	(118)
Less: Net income attributable to non-controlling interests	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	32,004	(118)
Preferred stock dividends	0	0
Net income (loss) available to common stockholders	32,004	(118)
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	296,837	330,106
Services revenue	11,225	15,799
Net product sales and services revenue	308,062	345,905
License and royalty revenue	2,558	4,363
Net revenue	310,620	350,268
Cost of net product sales	165,982	182,406
Cost of services revenue	8,040	8,440
Cost of net product sales and services revenue	174,022	190,846
Cost of license and royalty revenue	4,123	4,044
Cost of net revenue	178,145	194,890
Gross profit (loss)	132,475	155,378
Operating expenses:
Research and development	8,469	10,795
Sales and marketing	44,012	54,592
General and administrative	37,155	34,398
Impairment and (gain) loss on dispositions, net	(3,810)	(32,339)
Operating income (loss)	46,649	87,932
Interest expense, including amortization of original issue discounts and deferred financing costs	(3,067)	(4,043)
Other income (expense), net	(1,139)	(2,221)
Income (loss) before provision (benefit) for income taxes	42,443	81,668
Provision (benefit) for income taxes	(404)	11,717
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	42,847	69,951
Equity in earnings of subsidiaries, net of tax	0	0
Equity earnings of unconsolidated entities, net of tax	4,581	3,568
Income (loss) from continuing operations		73,519
Income (loss) from discontinued operations, net of tax		0
Net income (loss)	47,428	73,519
Less: Net income attributable to non-controlling interests	103	88
Net income (loss) attributable to Alere Inc. and Subsidiaries	47,325	73,431
Preferred stock dividends	0	0
Net income (loss) available to common stockholders	47,325	73,431
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	(61,446)	(60,806)
Services revenue		0
Net product sales and services revenue	(61,446)	(60,806)
License and royalty revenue	(2,749)	(2,862)
Net revenue	(64,195)	(63,668)
Cost of net product sales	(53,393)	(55,016)
Cost of services revenue	(7,435)	(6,901)
Cost of net product sales and services revenue	(60,828)	(61,917)
Cost of license and royalty revenue	(2,749)	(2,862)
Cost of net revenue	(63,577)	(64,779)
Gross profit (loss)	(618)	1,111
Operating expenses:
Research and development	0	0
Sales and marketing	0	0
General and administrative	0	0
Impairment and (gain) loss on dispositions, net	0	0
Operating income (loss)	(618)	1,111
Interest expense, including amortization of original issue discounts and deferred financing costs	4,700	6,995
Other income (expense), net	(4,700)	(6,995)
Income (loss) before provision (benefit) for income taxes	(618)	1,111
Provision (benefit) for income taxes	0	346
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(618)	765
Equity in earnings of subsidiaries, net of tax	(78,586)	(74,133)
Equity earnings of unconsolidated entities, net of tax	(228)	(33)
Income (loss) from continuing operations		(73,401)
Income (loss) from discontinued operations, net of tax		0
Net income (loss)	(79,432)	(73,401)
Less: Net income attributable to non-controlling interests	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(79,432)	(73,401)
Preferred stock dividends	0	0
Net income (loss) available to common stockholders	$ (79,432)	$ (73,401)

Guarantor Financial Informati90

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$ (9,977)	$ 210,428
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	22,193	(80,342)
Minimum pension liability adjustment	155	(1,382)
Other comprehensive income (loss), before tax	22,348	(81,724)
Income tax benefit related to items of other comprehensive income	0	0
Other comprehensive income (loss), net of tax	22,348	(81,724)
Comprehensive income (loss)	12,371	128,704
Less: Comprehensive income attributable to non-controlling interests	103	88
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	12,268	128,616
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(9,977)	210,428
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	115	(657)
Minimum pension liability adjustment	0	0
Other comprehensive income (loss), before tax	115	(657)
Income tax benefit related to items of other comprehensive income	0	0
Other comprehensive income (loss), net of tax	115	(657)
Comprehensive income (loss)	(9,862)	209,771
Less: Comprehensive income attributable to non-controlling interests	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(9,862)	209,771
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	32,004	(118)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(129)	(572)
Minimum pension liability adjustment	0	0
Other comprehensive income (loss), before tax	(129)	(572)
Income tax benefit related to items of other comprehensive income	0	0
Other comprehensive income (loss), net of tax	(129)	(572)
Comprehensive income (loss)	31,875	(690)
Less: Comprehensive income attributable to non-controlling interests	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	31,875	(690)
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	47,428	73,519
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	22,207	(79,113)
Minimum pension liability adjustment	155	(1,382)
Other comprehensive income (loss), before tax	22,362	(80,495)
Income tax benefit related to items of other comprehensive income	0	0
Other comprehensive income (loss), net of tax	22,362	(80,495)
Comprehensive income (loss)	69,790	(6,976)
Less: Comprehensive income attributable to non-controlling interests	103	88
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	69,687	(7,064)
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(79,432)	(73,401)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	0	0
Minimum pension liability adjustment	0	0
Other comprehensive income (loss), before tax	0	0
Income tax benefit related to items of other comprehensive income	0	0
Other comprehensive income (loss), net of tax	0	0
Comprehensive income (loss)	(79,432)	(73,401)
Less: Comprehensive income attributable to non-controlling interests	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (79,432)	$ (73,401)

Guarantor Financial Informati91

Guarantor Financial Information - Consolidating Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Jan. 09, 2015
Current assets:
Cash and cash equivalents	$ 490,663	$ 502,200	$ 414,495	$ 378,461
Restricted cash	6,166	5,694
Marketable securities	71	164
Accounts receivable, net of allowances	459,292	445,833
Inventories, net	350,931	347,001
Deferred tax assets	0	0
Prepaid expenses and other current assets	144,369	152,233
Assets held for sale - current	0	4,165
Intercompany receivables	0	0
Total current assets	1,451,492	1,457,290
Property, plant and equipment, net	445,218	446,039
Goodwill	2,839,692	2,836,915
Other intangible assets with indefinite lives	28,760	28,110
Finite-lived intangible assets, net	962,633	997,281
Restricted cash	43,388	43,228
Other non-current assets	17,927	18,078
Investments in subsidiaries	0	0
Investments in unconsolidated entities	74,744	65,333
Deferred tax assets	16,124	13,993
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	11,813	13,337
Intercompany notes receivables	0	0
Total assets	5,895,308	5,923,121
Current liabilities:
Short-term debt and current portion of long-term debt	193,044	199,992
Current portion of capital lease obligations	4,048	3,962
Accounts payable	165,800	195,752
Accrued expenses and other current liabilities	315,995	324,465
Liabilities related to assets held for sale - current	0	363
Intercompany payables	0	0
Total current liabilities	678,887	724,534
Long-term liabilities:
Long-term debt, net of current portion	2,823,654	2,831,166
Capital lease obligations, net of current portion	7,654	7,181
Deferred tax liabilities	144,483	147,618
Other long-term liabilities	155,842	154,193
Intercompany notes payables	0	0
Total long-term liabilities	3,131,633	3,140,158
Total stockholders' equity	2,080,423	2,054,165
Non-controlling interests	4,365	4,264
Total equity	2,084,788	2,058,429
Total liabilities and equity	5,895,308	5,923,121
Issuer [Member]
Current assets:
Cash and cash equivalents	97,071	139,153	13,827	2,149
Restricted cash	1,763	1,250
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	0	0
Deferred tax assets	(52,409)	(52,410)
Prepaid expenses and other current assets	8,726	7,575
Assets held for sale - current		0
Intercompany receivables	186,846	620,838
Total current assets	241,997	716,406
Property, plant and equipment, net	30,124	31,384
Goodwill	0	0
Other intangible assets with indefinite lives	0	0
Finite-lived intangible assets, net	2,873	2,951
Restricted cash	0	0
Other non-current assets	794	804
Investments in subsidiaries	3,399,545	3,294,857
Investments in unconsolidated entities	687	502
Deferred tax assets	(14,079)	(14,078)
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	11,813	13,337
Intercompany notes receivables	1,878,821	1,905,188
Total assets	5,556,092	5,954,868
Current liabilities:
Short-term debt and current portion of long-term debt	190,073	197,084
Current portion of capital lease obligations		0
Accounts payable	12,288	15,981
Accrued expenses and other current liabilities	(546,246)	(554,350)
Liabilities related to assets held for sale - current		0
Intercompany payables	688,995	1,122,042
Total current liabilities	345,110	780,757
Long-term liabilities:
Long-term debt, net of current portion	2,777,081	2,784,913
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	(158,407)	(157,708)
Other long-term liabilities	15,329	14,962
Intercompany notes payables	496,556	477,779
Total long-term liabilities	3,130,559	3,119,946
Total stockholders' equity	2,080,423	2,054,165
Non-controlling interests	0	0
Total equity	2,080,423	2,054,165
Total liabilities and equity	5,556,092	5,954,868
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	4,482	21,150	87,557	69,154
Restricted cash	0	0
Marketable securities	71	164
Accounts receivable, net of allowances	200,537	192,591
Inventories, net	171,739	173,383
Deferred tax assets	31,285	31,285
Prepaid expenses and other current assets	25,789	27,095
Assets held for sale - current		0
Intercompany receivables	766,023	812,957
Total current assets	1,199,926	1,258,625
Property, plant and equipment, net	225,834	228,065
Goodwill	1,823,647	1,823,919
Other intangible assets with indefinite lives	7,608	7,638
Finite-lived intangible assets, net	596,886	627,269
Restricted cash	0	0
Other non-current assets	2,227	2,340
Investments in subsidiaries	158,195	158,195
Investments in unconsolidated entities	14,765	14,764
Deferred tax assets	12	(14)
Non-current income tax receivable	0	0
Assets held for sale - non-current	0	0
Intercompany notes receivables	708,709	672,032
Total assets	4,737,809	4,792,833
Current liabilities:
Short-term debt and current portion of long-term debt	0	0
Current portion of capital lease obligations	2,106	2,018
Accounts payable	70,302	76,890
Accrued expenses and other current liabilities	646,418	650,632
Liabilities related to assets held for sale - current		0
Intercompany payables	186,318	249,553
Total current liabilities	905,144	979,093
Long-term liabilities:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	1,636	840
Deferred tax liabilities	250,394	250,495
Other long-term liabilities	59,504	59,309
Intercompany notes payables	1,165,042	1,181,168
Total long-term liabilities	1,476,576	1,491,812
Total stockholders' equity	2,356,089	2,321,928
Non-controlling interests	0	0
Total equity	2,356,089	2,321,928
Total liabilities and equity	4,737,809	4,792,833
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	389,110	341,897	313,111	307,158
Restricted cash	4,403	4,444
Marketable securities	0	0
Accounts receivable, net of allowances	258,755	253,242
Inventories, net	204,256	194,192
Deferred tax assets	23,244	23,244
Prepaid expenses and other current assets	103,276	110,961
Assets held for sale - current		4,165
Intercompany receivables	129,311	50,691
Total current assets	1,112,355	982,836
Property, plant and equipment, net	191,373	188,084
Goodwill	1,016,045	1,012,996
Other intangible assets with indefinite lives	21,211	20,531
Finite-lived intangible assets, net	365,913	370,261
Restricted cash	43,388	43,228
Other non-current assets	15,414	15,380
Investments in subsidiaries	57,650	57,650
Investments in unconsolidated entities	43,069	37,947
Deferred tax assets	30,191	28,085
Non-current income tax receivable	0	0
Assets held for sale - non-current	0	0
Intercompany notes receivables	5,900	6,900
Total assets	2,902,509	2,763,898
Current liabilities:
Short-term debt and current portion of long-term debt	2,971	2,908
Current portion of capital lease obligations	1,942	1,944
Accounts payable	83,210	102,881
Accrued expenses and other current liabilities	213,609	225,944
Liabilities related to assets held for sale - current		363
Intercompany payables	206,867	112,891
Total current liabilities	508,599	446,931
Long-term liabilities:
Long-term debt, net of current portion	46,573	46,253
Capital lease obligations, net of current portion	6,018	6,341
Deferred tax liabilities	52,414	54,749
Other long-term liabilities	81,517	80,369
Intercompany notes payables	931,832	925,173
Total long-term liabilities	1,118,354	1,112,885
Total stockholders' equity	1,271,191	1,199,818
Non-controlling interests	4,365	4,264
Total equity	1,275,556	1,204,082
Total liabilities and equity	2,902,509	2,763,898
Eliminations [Member]
Current assets:
Cash and cash equivalents	0	0	$ 0	$ 0
Restricted cash	0	0
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	(25,064)	(20,574)
Deferred tax assets	(2,120)	(2,119)
Prepaid expenses and other current assets	6,578	6,602
Assets held for sale - current		0
Intercompany receivables	(1,082,180)	(1,484,486)
Total current assets	(1,102,786)	(1,500,577)
Property, plant and equipment, net	(2,113)	(1,494)
Goodwill	0	0
Other intangible assets with indefinite lives	(59)	(59)
Finite-lived intangible assets, net	(3,039)	(3,200)
Restricted cash	0	0
Other non-current assets	(508)	(446)
Investments in subsidiaries	(3,615,390)	(3,510,702)
Investments in unconsolidated entities	16,223	12,120
Deferred tax assets	0	0
Non-current income tax receivable	0	0
Assets held for sale - non-current	0	0
Intercompany notes receivables	(2,593,430)	(2,584,120)
Total assets	(7,301,102)	(7,588,478)
Current liabilities:
Short-term debt and current portion of long-term debt	0	0
Current portion of capital lease obligations	0	0
Accounts payable	0	0
Accrued expenses and other current liabilities	2,214	2,239
Liabilities related to assets held for sale - current		0
Intercompany payables	(1,082,180)	(1,484,486)
Total current liabilities	(1,079,966)	(1,482,247)
Long-term liabilities:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	82	82
Other long-term liabilities	(508)	(447)
Intercompany notes payables	(2,593,430)	(2,584,120)
Total long-term liabilities	(2,593,856)	(2,584,485)
Total stockholders' equity	(3,627,280)	(3,521,746)
Non-controlling interests	0	0
Total equity	(3,627,280)	(3,521,746)
Total liabilities and equity	$ (7,301,102)	$ (7,588,478)

Guarantor Financial Informati92

Guarantor Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows from Operating Activities:
Net income (loss)	$ (9,977)	$ 210,428
Income (loss) from discontinued operations, net of tax	0	216,777
Income (loss) from continuing operations	(9,977)	(6,349)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	2,236	3,946
Depreciation and amortization	72,504	74,414
Non-cash stock-based compensation expense	9,602	5,149
Impairment of inventory	1,349	78
Impairment of long-lived assets	608	(69)
Loss on disposition of fixed assets	323	1,391
Equity earnings of unconsolidated entities, net of tax	(5,034)	(3,959)
Deferred income taxes	(6,812)	(21,418)
Loss related to impairment and net (gain) loss on dispositions	(3,810)	34,792
Other non-cash items	2,496	8,181
Non-cash change in fair value of contingent purchase price consideration	142	(14,035)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(9,199)	(11,755)
Inventories, net	(14,147)	(29,705)
Prepaid expenses and other current assets	(5,796)	18,980
Accounts payable	(31,542)	(18,648)
Accrued expenses and other current liabilities	(7,413)	(1,282)
Other non-current liabilities	14	(7,348)
Cash paid for contingent consideration	(143)	(3,654)
Intercompany payable (receivable)	0	0
Net cash (used in) provided by continuing operations	(4,599)	28,709
Net cash provided by discontinued operations	0	318
Net cash (used in) provided by operating activities	(4,599)	29,027
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	(436)	71
Purchases of property, plant and equipment	(14,504)	(25,647)
Proceeds from sale of property, plant and equipment	612	808
Cash received from (used in) disposition, net of cash divested	21,470	581,185
Cash paid for business acquisitions, net of cash acquired	(5,945)	0
Cash received from sales of marketable securities	93	86
Cash received from equity method investments	2,205	0
Cash paid for investments	(184)	0
(Increase) decrease in other assets	(540)	913
Net cash provided by (used in) continuing operations	2,771	557,416
Net cash used in discontinued operations	0	(209)
Net cash provided by (used in) investing activities	2,771	557,207
Cash Flows from Financing Activities:
Cash paid for financing costs	(1)	(59)
Cash paid for contingent purchase price consideration	(145)	(4,696)
Proceeds from issuance of common stock, net of issuance costs	11,124	34,632
Proceeds from issuance of long-term debt	325	15
Payments on short-term debt	0	(321)
Payments on long-term debt	(17,275)	(463,011)
Net payments under revolving credit facilities	(127)	(127,050)
Cash paid for dividends	(5,323)	(5,323)
Principal payments on capital lease obligations	(1,107)	(1,484)
Net cash used in continuing operations	(12,529)	(567,297)
Net cash used in discontinued operations	0	(76)
Net cash used in financing activities	(12,529)	(567,373)
Foreign exchange effect on cash and cash equivalents	2,820	(6,127)
Net increase (decrease) in cash and cash equivalents	(11,537)	12,734
Cash and cash equivalents, beginning of period - continuing operations	502,200	378,461
Cash and cash equivalents, beginning of period - discontinued operations	0	23,300
Cash and cash equivalents of continuing operations, end of period	490,663	414,495
Issuer [Member]
Cash Flows from Operating Activities:
Net income (loss)	(9,977)	210,428
Income (loss) from discontinued operations, net of tax		218,689
Income (loss) from continuing operations		(8,261)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	(78,586)	(74,133)
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	2,188	3,917
Depreciation and amortization	2,203	1,650
Non-cash stock-based compensation expense	5,069	2,435
Impairment of inventory	0	0
Impairment of long-lived assets	0	0
Loss on disposition of fixed assets	15	0
Equity earnings of unconsolidated entities, net of tax	(681)	(424)
Deferred income taxes	0	9
Loss related to impairment and net (gain) loss on dispositions	0	36,523
Other non-cash items	105	1,686
Non-cash change in fair value of contingent purchase price consideration	(1,000)	300
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	0	0
Inventories, net	0	0
Prepaid expenses and other current assets	(1,137)	(4,680)
Accounts payable	(3,694)	(7,637)
Accrued expenses and other current liabilities	9,892	(1,681)
Other non-current liabilities	(616)	(5,624)
Cash paid for contingent consideration	(143)	(3,641)
Intercompany payable (receivable)	46,244	49,312
Net cash (used in) provided by continuing operations		(10,249)
Net cash provided by discontinued operations		0
Net cash (used in) provided by operating activities	(30,118)	(10,249)
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	(513)	1,919
Purchases of property, plant and equipment	(841)	(3,274)
Proceeds from sale of property, plant and equipment	0	0
Cash received from (used in) disposition, net of cash divested	(1,337)	587,637
Cash paid for business acquisitions, net of cash acquired	0
Cash received from sales of marketable securities	0	0
Cash received from equity method investments	2,205
Cash paid for investments	(184)
(Increase) decrease in other assets	(64)	348
Net cash provided by (used in) continuing operations		586,630
Net cash used in discontinued operations		0
Net cash provided by (used in) investing activities	(734)	586,630
Cash Flows from Financing Activities:
Cash paid for financing costs	(1)	(59)
Cash paid for contingent purchase price consideration	0	(3,953)
Proceeds from issuance of common stock, net of issuance costs	11,124	34,632
Proceeds from issuance of long-term debt	0	0
Payments on short-term debt		0
Payments on long-term debt	(17,030)	(463,000)
Net payments under revolving credit facilities	0	(127,000)
Cash paid for dividends	(5,323)	(5,323)
Principal payments on capital lease obligations	0	0
Net cash used in continuing operations		(564,703)
Net cash used in discontinued operations		0
Net cash used in financing activities	(11,230)	(564,703)
Foreign exchange effect on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	(42,082)	11,678
Cash and cash equivalents, beginning of period - continuing operations	139,153	2,149
Cash and cash equivalents, beginning of period - discontinued operations		0
Cash and cash equivalents of continuing operations, end of period	97,071	13,827
Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	32,004	(118)
Income (loss) from discontinued operations, net of tax		(1,912)
Income (loss) from continuing operations		1,794
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	4	7
Depreciation and amortization	45,691	42,097
Non-cash stock-based compensation expense	2,287	1,239
Impairment of inventory	0	133
Impairment of long-lived assets	608	28
Loss on disposition of fixed assets	8	1,346
Equity earnings of unconsolidated entities, net of tax	0	0
Deferred income taxes	(100)	(22,090)
Loss related to impairment and net (gain) loss on dispositions	0	30,608
Other non-cash items	303	(749)
Non-cash change in fair value of contingent purchase price consideration	1,199	171
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(7,875)	4,728
Inventories, net	(6,681)	(14,699)
Prepaid expenses and other current assets	1,514	13,671
Accounts payable	(6,773)	(470)
Accrued expenses and other current liabilities	(2,703)	13,668
Other non-current liabilities	(870)	(191)
Cash paid for contingent consideration	0	0
Intercompany payable (receivable)	(69,205)	(57,097)
Net cash (used in) provided by continuing operations		14,194
Net cash provided by discontinued operations		318
Net cash (used in) provided by operating activities	(10,589)	14,512
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	0	0
Purchases of property, plant and equipment	(5,615)	(10,154)
Proceeds from sale of property, plant and equipment	40	0
Cash received from (used in) disposition, net of cash divested	0	(8,584)
Cash paid for business acquisitions, net of cash acquired	0
Cash received from sales of marketable securities	93	86
Cash received from equity method investments	0
Cash paid for investments	0
(Increase) decrease in other assets	(98)	362
Net cash provided by (used in) continuing operations		(18,290)
Net cash used in discontinued operations		(209)
Net cash provided by (used in) investing activities	(5,580)	(18,499)
Cash Flows from Financing Activities:
Cash paid for financing costs	0	0
Cash paid for contingent purchase price consideration	0	0
Proceeds from issuance of common stock, net of issuance costs	0	0
Proceeds from issuance of long-term debt	0	0
Payments on short-term debt		0
Payments on long-term debt	0	0
Net payments under revolving credit facilities	0	0
Cash paid for dividends	0	0
Principal payments on capital lease obligations	(659)	(627)
Net cash used in continuing operations		(627)
Net cash used in discontinued operations		(76)
Net cash used in financing activities	(659)	(703)
Foreign exchange effect on cash and cash equivalents	160	(207)
Net increase (decrease) in cash and cash equivalents	(16,668)	(4,897)
Cash and cash equivalents, beginning of period - continuing operations	21,150	69,154
Cash and cash equivalents, beginning of period - discontinued operations		23,300
Cash and cash equivalents of continuing operations, end of period	4,482	87,557
Non-Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	47,428	73,519
Income (loss) from discontinued operations, net of tax		0
Income (loss) from continuing operations		73,519
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	44	22
Depreciation and amortization	23,722	30,654
Non-cash stock-based compensation expense	2,246	1,475
Impairment of inventory	1,349	(55)
Impairment of long-lived assets	0	(97)
Loss on disposition of fixed assets	300	45
Equity earnings of unconsolidated entities, net of tax	(4,581)	(3,568)
Deferred income taxes	(6,712)	318
Loss related to impairment and net (gain) loss on dispositions	(3,810)	(32,339)
Other non-cash items	2,088	7,245
Non-cash change in fair value of contingent purchase price consideration	(57)	(14,506)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(1,324)	(16,483)
Inventories, net	(7,196)	(13,693)
Prepaid expenses and other current assets	(6,198)	15,179
Accounts payable	(21,075)	(10,541)
Accrued expenses and other current liabilities	(14,577)	(18,881)
Other non-current liabilities	1,562	(1,060)
Cash paid for contingent consideration	0	(13)
Intercompany payable (receivable)	22,961	7,784
Net cash (used in) provided by continuing operations		25,005
Net cash provided by discontinued operations		0
Net cash (used in) provided by operating activities	36,170	25,005
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	77	(1,848)
Purchases of property, plant and equipment	(8,048)	(12,409)
Proceeds from sale of property, plant and equipment	572	808
Cash received from (used in) disposition, net of cash divested	22,807	2,132
Cash paid for business acquisitions, net of cash acquired	(5,945)
Cash received from sales of marketable securities	0	0
Cash received from equity method investments	0
Cash paid for investments	0
(Increase) decrease in other assets	(440)	152
Net cash provided by (used in) continuing operations		(11,165)
Net cash used in discontinued operations		0
Net cash provided by (used in) investing activities	9,023	(11,165)
Cash Flows from Financing Activities:
Cash paid for financing costs	0	0
Cash paid for contingent purchase price consideration	(145)	(743)
Proceeds from issuance of common stock, net of issuance costs	0	0
Proceeds from issuance of long-term debt	325	15
Payments on short-term debt		(321)
Payments on long-term debt	(245)	(11)
Net payments under revolving credit facilities	(127)	(50)
Cash paid for dividends	0	0
Principal payments on capital lease obligations	(448)	(857)
Net cash used in continuing operations		(1,967)
Net cash used in discontinued operations		0
Net cash used in financing activities	(640)	(1,967)
Foreign exchange effect on cash and cash equivalents	2,660	(5,920)
Net increase (decrease) in cash and cash equivalents	47,213	5,953
Cash and cash equivalents, beginning of period - continuing operations	341,897	307,158
Cash and cash equivalents, beginning of period - discontinued operations		0
Cash and cash equivalents of continuing operations, end of period	389,110	313,111
Eliminations [Member]
Cash Flows from Operating Activities:
Net income (loss)	(79,432)	(73,401)
Income (loss) from discontinued operations, net of tax		0
Income (loss) from continuing operations		(73,401)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	78,586	74,133
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	0	0
Depreciation and amortization	888	13
Non-cash stock-based compensation expense	0	0
Impairment of inventory	0	0
Impairment of long-lived assets	0	0
Loss on disposition of fixed assets	0	0
Equity earnings of unconsolidated entities, net of tax	228	33
Deferred income taxes	0	345
Loss related to impairment and net (gain) loss on dispositions	0	0
Other non-cash items	0	(1)
Non-cash change in fair value of contingent purchase price consideration	0	0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	0	0
Inventories, net	(270)	(1,313)
Prepaid expenses and other current assets	25	(5,190)
Accounts payable	0	0
Accrued expenses and other current liabilities	(25)	5,612
Other non-current liabilities	(62)	(473)
Cash paid for contingent consideration	0	0
Intercompany payable (receivable)	0	1
Net cash (used in) provided by continuing operations		(241)
Net cash provided by discontinued operations		0
Net cash (used in) provided by operating activities	(62)	(241)
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	0	0
Purchases of property, plant and equipment	0	190
Proceeds from sale of property, plant and equipment	0	0
Cash received from (used in) disposition, net of cash divested	0	0
Cash paid for business acquisitions, net of cash acquired	0
Cash received from sales of marketable securities	0	0
Cash received from equity method investments	0
Cash paid for investments	0
(Increase) decrease in other assets	62	51
Net cash provided by (used in) continuing operations		241
Net cash used in discontinued operations		0
Net cash provided by (used in) investing activities	62	241
Cash Flows from Financing Activities:
Cash paid for financing costs	0	0
Cash paid for contingent purchase price consideration	0	0
Proceeds from issuance of common stock, net of issuance costs	0	0
Proceeds from issuance of long-term debt	0	0
Payments on short-term debt		0
Payments on long-term debt	0	0
Net payments under revolving credit facilities	0	0
Cash paid for dividends	0	0
Principal payments on capital lease obligations	0	0
Net cash used in continuing operations		0
Net cash used in discontinued operations		0
Net cash used in financing activities	0	0
Foreign exchange effect on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period - continuing operations	0	0
Cash and cash equivalents, beginning of period - discontinued operations		0
Cash and cash equivalents of continuing operations, end of period	$ 0	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ in Thousands	May 15, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Repayment of long term debt		$ 17,275	$ 463,011
INRatio 2 PT/INR Monitoring System Voluntary Withdrawal [Member]
Subsequent Event [Line Items]
Restructuring and impairment charges		16,000			$ 38,000
Accelerated amortization of intangible assets		4,100
Accelerated depreciation of tangible assets		$ 700
3% Convertible Senior Subordinated Notes [Member] | Subsequent Events [Member]
Subsequent Event [Line Items]
Repayment of long term debt	$ 152,000
3% Convertible Senior Subordinated Notes [Member] | Subsequent Events [Member] | Cash [Member]
Subsequent Event [Line Items]
Repayment of long term debt	27,000
3% Convertible Senior Subordinated Notes [Member] | Subsequent Events [Member] | Secured Credit Facility Revolving Line-Of-Credit [Member]
Subsequent Event [Line Items]
Repayment of long term debt	$ 125,000
Scenario, Forecast [Member] | INRatio 2 PT/INR Monitoring System Voluntary Withdrawal [Member]
Subsequent Event [Line Items]
Accelerated amortization of intangible assets				$ 12,300
Accelerated depreciation of tangible assets				2,400
One time cash expenditures				$ 2,000